Clinical Development
FTY720 (Fingolimod)
Protocol No. CFTY720D2399 / [STUDY_ID_REMOVED]
A single arm, open -label, multicenter study ev aluating the 
long -term safety and tolerability of 0.5 mg fingolimod 
(FTY720) administered orally once daily in patients w ith 
relapsing forms of multiple sclerosis (LONGTERMS)
Document type: Amended Protocol Version
EUDRACT number: 2010 -020515 -37
Version number: v11Clean
Development phase: IIIb
Release date: 1 Apr 2016
Template Version 26-May-2009
Property of [COMPANY_001]
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of [COMPANY_001]

[COMPANY_001] Confidential Page 2
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Table of contents
Table of contents ................................................................................................................. [ADDRESS_685014] of abbreviations ............................................................................................................ 6
Glossary  of terms ................................................................................................................. 9
Amendment 11 -
present........................................................................................................... 10
Amendment 10 –
March 2016.................................................................................................. 11
Amendment 9 –September 2015 ............................................................................................. 12
Amendment 8 –
August 2014................................................................................................... 13
Amendment 7 –
August 2013................................................................................................... 14
Amendment 6 –July 2012 ................................ ................................ ................................ ........ 15
Amendment 5- February  2012 ................................................................................................... 17
Amendment 4
-October 2011 .................................................................................................... 18
Amendment 3
-May 2011.......................................................................................................... 20
Amendment 2
-March 2011 ....................................................................................................... 21
Amendment 1
-July 2010 .......................................................................................................... 22
Protocol sy nopsis ............................................................................................................... 23
1Introduction ....................................................................................................................... 27
1.1 Background ............................................................................................................ 27
1.2 Purpose .................................................................................................................. 29
2Study  objectives ................................................................................................................. 29
2.1 Primary  objectives ................................................................................................. 29
2.2 Secondary  objectives ............................................................................................. 30
30
3Investigational plan ........................................................................................................... 30
3.1 Study  design ........................................................................................................... 30
3.2 Rationale of study  design ....................................................................................... 31
3.3 Rationale of dose/regimen, duration of treatment ................................................. 31
3.4
Rationale for choice of comparator ....................................................................... 32
3.5 Purpose and timing of interim anal yses/design adapt ations .................................. 32
4Population ................................ ................................ ................................ .......................... 32
4.1 Inclusion criteria .................................................................................................... 32
4.2 Exclusion criteria ................................................................................................... 32
5Treatment ........................................................................................................................... 34
5.1 Investigational and control treatment .................................................................... 34
5.2 Treatment arms ...................................................................................................... 34

[COMPANY_001] Confidential Page 3
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
5.[ADDRESS_685015] -study  treatment ................................ .......... 40
5.5.12 Early study termination ......................................................................... 40
6
Visit schedule and assessments ................................ ................................ ......................... 40
6.1 Patient demographics/other baseline characteristics ............................................. 46
6.2 Previous Study  Details ........................................................................................... 46
6.3 Treatment exposure and compliance ..................................................................... 47
6.4 Efficacy .................................................................................................................. 47
6.4.1 MS relapse ............................................................................................. 47
6.4.2 Expanded Disability  Status Scale (EDSS) ............................................ 48
6.4.3 Magnetic resonance imaging (MRI) ..................................................... 48
6.4.4
Multiple Sclerosis Functional Composite (MSFC)............................... 49
6.4.5 Appropriateness of efficacy  assessments .............................................. 50
6.5 Safet y
..................................................................................................................... 50
6.5.1 Physical/neurological examination ....................................................... 50
6.5.2 Skin assessments ................................................................................... 51
6.5.3 Vital signs .............................................................................................. 51
6.5.4 Laboratory  evaluations .......................................................................... 51
6.5.5 Ophthalmologic exams/ Optical coherence tomograph y (OCT) .......... 53
6.5.6 Electroca rdiogram (ECG) ..................................................................... 53
6.5.7 Pulmonary  function tests ....................................................................... 53
6.5.8 Pregnancy  and assessments of fertility ................................................. 54
6.5.9 Appropriateness of safety  measurements .............................................. 54

[COMPANY_001] Confidential Page 4
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
55
55
55
56
56
56
56
56
7Safet y monitoring .............................................................................................................. 57
7.1 Adverse events ....................................................................................................... 57
7.2 Serious adverse event reporting ............................................................................. 58
7.3 Pregnancies ............................................................................................................ 59
8Data review and database management ............................................................................. 59
8.1 Site monitoring ...................................................................................................... 59
8.2
Data collection....................................................................................................... 60
8.3 Database management and quality  control ................................ ............................ 60
9Data analy sis................................ ................................ ................................ ...................... 60
9.1 Analy sis sets .......................................................................................................... 61
9.1.1 Subgroup ............................................................................................... 62
9.2
Patient demographics and other baseline characteristics....................................... 62
9.3 Treatments (stud y drug, rescue medication, other concomitant therapi[INVESTIGATOR_014], 
compliance) ............................................................................................................ 62
9.4 Analy sis of the primary  variable(s) ....................................................................... 62
9.4.1 Variable ................................................................................................. 62
9.4.2 Handling of missing values/censoring/discontinuations ....................... 64
9.4.3 Supportive anal yses............................................................................... 64
9.5 Analy sis of secondary  variables
............................................................................ 64
9.5.1 Efficacy  variables
.................................................................................. 64
66
9.6
Sample size calculation.......................................................................................... 66
9.7 Power for anal ysis of key secondary  variables ...................................................... 67
9.8 Interim anal yses..................................................................................................... 67
10
Ethical considerations........................................................................................................ 67
10.1 Regulatory
 and ethical compliance ........................................................................ 67
10.2 Informed consent procedures
................................................................................. 67
10.3 Responsibilities of the investigator and IRB/IEC ................................ .................. 68

[COMPANY_001] Confidential Page 5
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
10.4 Publication of study  protocol and results ................................ ............................... 68
11Protocol adherence ............................................................................................................ 68
11.1 Protocol Amendments ........................................................................................... 68
12References (availabl e upon request) .................................................................................. 69
13Appendices ........................................................................................................................ 70
Appendix 1:  Clinically  notable laboratory  values and vital signs .................................... 70
Appendix 2:  Multiple Sclerosis Functional Composite Measure (MSFC) ...................... 72
Appendix 3:  [LOCATION_001] Heart Association Functional Classification .............................. 74
Appendix 4:  Guidance for Monitoring of patients taking their first dose of the study  
drug .................................................................................................................................... 75
Appendix 5:  Guidance on safet y monitoring .................................................................... 78
Appendix 6:  L iver event and Laboratory  trigger D efinitions and Follow -up 
Requirements ..................................................................................................................... 81
Appendix 7: Guidance for Ophthalmic Monitoring
.......................................................... 83
Appendix 8: EDSS Assessment Criteria
........................................................................... [ADDRESS_685016] of tables
Table 6
-1 Assessment schedule (Study  Part One) ................................ ................. 41
Table 6-2 Assessment schedule (Study  Part Two) ................................................ 44
Liver Event and Laboratory  Trigger Definitions ................................ ................................ ......81
Follow Up Requirements for Liver Events and Laboratory Triggers ...................................... 81

[COMPANY_001] Confidential Page 6
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
List of abbreviations
9-HPT 9-hole peg test
AE adverse event
ACTH
adrenocorticotropic hormone
Alb albumin
ALP alkaline phosphotase
ALT alanine aminotransferase
ARR annual relapse rate
AST aspartate aminotransferase
AV atrioventricular
BPM beats per minute
eCRF electronic case report/record form
CPO Country  Pharma Organization
CRO Contract Research Organization
CSR Clinical Study  Report
DLCO carbon monoxide diffusing capacity test
DS&E Drug Safet y & Epi[INVESTIGATOR_527614]1 forced expi[INVESTIGATOR_527615] [ADDRESS_685017]
GGT gamma -glutam yl-transferase
HbA1c glycated hemog lobin
HCG human chorionic gonadotropin
HR heart rate
IB investigator’s brochure

[COMPANY_001] Confidential Page 7
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
ICH International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
ID identification
IEC Independent Ethics Committee
IFN interferon
IN Investigator Notification
IRB Institutional Review Board
IRT Interactive Response Technology
LFT liver function test
LN lymph nodes
LUC large unstained cells
MedDRA medical dictionary  for regulatory  activities
MRI magnetic resonance imaging
MS multiple sclerosis
NPDR non-proliferative diabetic retinopathy
OCT optical coherence tomography
p.o. by [CONTACT_527637]/INR prothrombin time / international normalized ratio
RBC red blood cell
RMP risk management plan
RRMS relapsing remitting multiple sclerosis
SAE serious adverse event
s.c. subcutane ously
SPMS secondary  progressive multiple sclerosis
S[LOCATION_003]R suspected unexpected serious adverse r eactions

[COMPANY_001] Confidential Page 8
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
TBL total bilirubin
ULN upper limit of normal range

[COMPANY_001] Confidential Page 9
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Glossary  of terms
Assessment A procedure used to generate data required by [CONTACT_220425]/time of patient entry into the study; the point at which informed 
consent must be obtained (i.e. prior to starting any of the procedures 
described in the protocol)
Investigational drug The study drug whose properties are being tested in the study; this 
definition is con sistent with US CFR 21 Section 312.3 and is synonymous 
with “investigational new drug.”
Medication number A unique identifier on the label of each study drug package in studies that 
dispense study drug using an IVR system
Patient number A number assigned to each patient who enrolls in the study. W hen 
combined with the center number, a unique identifier is created for each 
patient in the study.
Period A minor subdivision of the study timeline; divides phases into smaller 
functional segmen ts such as screening, baseline, titration, washout, etc.
Premature patient withdrawal Point/time when the patient exits from the study prior to the planned 
completion of all study drug administration and assessments; at this time 
all study drug administra tion is discontinued and no further assessments 
are planned
Stage A major subdivision of the study timeline; begins and ends with major 
study milestones such as enrollment, randomization, completion of 
treatment, etc.
Stop study participation Point/time at which the patient came in for a final evaluation visit or when 
study drug was discontinued whichever is later
Study drug Any drug administered to the patient as part of the required study 
procedures; includes investigational drug and any control drugs
Study drug discontinuation Point/time when patient permanently stops taking study drug for any 
reason; may or may not also be the point/time of premature patient
withdrawal
Variable Information used in the data analysis; derived directly or indirectly from 
data collected using specified assessments at specified timepoints

[COMPANY_001] Confidential Page 10
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Amendment [ADDRESS_685018] 
(IRBs)/Independent Ethics Committee ( IECs) and Health Authorities .
The changes described in this amended protocol are non-substantial and do not require 
IRB/IEC approval prior to implementation.

[COMPANY_001] Confidential Page 11
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Summary  of previous amendments 
Amendment 10 –March 2016
Amendment Rationale
As the final label and reimbursement guidelines were unknown at the outset of the fingolimod 
clinical program, some patients enrolled in the core trials and subsequently  transitioned into 
this protocol are currently  ineligible for commerciall y reimbursed Gileny a.  Based on the 
assumption that continued study  participation means there is a positive benefit -risk paradigm 
for these patients, [COMPANY_001] elected to extend this protocol for up to two additional years, to 
allow continued fingolimod use until countri es and investigators can find alternate treatment 
solutions.  Therefore, this protocol is being amended to update the study  design, offering 
continued patient participation in a subset of patients (those unable to obtain access 
to/reimbursement for commerc ial Gilen ya) for an additional (approximately ) two years, 
through June 2018.  In keepi[INVESTIGATOR_527616], safety  and tolerabilit y 
data will continue to be collected during this time period.
This study  is ongoing with approximately  4,[ADDRESS_685019] 
continued access , while allowing for continued collection of long-term safety  and tolerability 
data.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
The major changes made to the protocol are summarized in this section. Other minor changes 
are incorporated directl y into the protocol. The major changes include the following:
Update s to Study  objectives (Section 2) , Study  design ( Section 3.1), Rationale of study  
design ( Section 3.2 ), Rationale
of dose/regimen, duration of treatment (Section 3.3) , 
Population ( Section 4), Study  completion and post -study  treatment ( Section 5.5.11 ), 
Discontinuation of study  treatment (Section 5.5.9) , Laboratory  evaluations (Section 6.5.4) , 
Data analy sis (Section 9) , Guidance on Safet y Monitoring (Section 13, Appendix 5) , and 
the Schedule of assessments ( Table 6-1) .
  Liver event and Laboratory  trigger 
Definitions and Follow -up Requirements (Section 13, Appendix 6) , and the Schedule of 
assessments for Part Two (Table 6 -2).

[COMPANY_001] Confidential Page 12
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee ( IECs) and Health Authorities .
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.
Amendment 9 –September 2015
Amendment rationale
The protocol is being amended to address safety  updates in the investigator brochure (Edition 
18) –in particular to provide additional guidance for safet y monitoring for opportunistic 
infections and for basal cell carcinoma.   Second, this amendment provides detail sregarding 
the Study  Completion visit scheduling for all patients, and re -introduces hematology  testing at 
every  visit.
Notably , there have been reports of isolated cases of cryptococcal meningitis in patients with 
relapsing MS receiving fingolimod. As a result, the fingolimod local product labeling will be 
updated to guide prescribers for vigilance, earl y detection, and diagnosis of such cases, should 
they occur. Similarly , the infection safet y monitoring guidance is being updated in this 
protocol.
Basal cell carcinoma has been reported in patients receiving fingolimod. The physical 
examination section has been amended to ask patients about any new or worsening skin 
lesions and to instruct investigators to refer patients to the dermatologist in cases where 
suspected precancerous or cancerous sk in lesions are identified.
This study  planned to end by 30-Jun-[ADDRESS_685020] 60 months or more of long-term 
safet y data for the majority  of Phase II/III patients .   Guidance regarding scheduling of the 
Study  Completion visit 
is provided in order to streamline the study closure processes, 
specificall y designating the Study Completion visit to occur at or shortly  after sixty  months of 
study  participation for those patients who would reach [ADDRESS_685021] their study  completion on or around 30 -Jun-
2016 (+/- 30 day  visit window), and patient who have alread y reached [ADDRESS_685022].
Hematology  testing has been re-instituted at the six monthly  visits (i.e., every  study visit) to 
provide additional ly mphocy te count information to study  sites.  
This study  is an ongoing study  with approximately  4,150 enrolled patients.  These changes 
will ensure that study  patients receive the same information and care that patients on 
commercial Gilen ya will receive, provide additional lymphocy te monitoring, and clarify  the 
upcoming stud y completion visit scheduling.

[COMPANY_001] Confidential Page 13
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Changes to the protocol
Changes tospecific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
The major changes made to the protocol are summarized in this section. Other minor changes 
are incorporated directl y into the protocol. The major changes include the following: 
Updates to the Background ( Section 1.1), Phy sical/ neurological exam (Section 6.5.1 ), 
Skin a ssessments ( Section 6.5.2), and Guidance on sa fety monitoring ( Appendix 5 ) based 
on investigator brochure (Edition 18) upda tes.
Updates to Study  design ( Section 3.1), Rationale of s tudy design ( Section 3.2 ), Population 
(Section 4), Study  comp letion and post -study  treatment ( Section 5.5.11), and the Schedule 
of assessments ( Table 6 -
1) related to Stud y Completion visit scheduling and/or re -
introduction of hematology  sampling at the [ADDRESS_685023] s
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.
Amendment 8 –August 2014
Amendment rationale 
The primary  objective of this study  is to evaluate the continued safet y and tolerability  of 
fingolimod over longer periods of time. The Gileny a Risk Management Plan ( RMP )provides 
guidance for the minimum saf ety monitoring required. During a review of the protocol, it was 
identified that the protocol has more stringent monitoring frequency  than recommended in the 
RMP and standard of care. Thus, in an effort to reduce patient and site burden, in addition to 
managing internal resources, some clinical monitoring has been amended to reflect current 
RMP guidance.
This is an ongoing study  withapproximately  4,[ADDRESS_685024] of care or the final study  results.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.

[COMPANY_001] Confidential Page 14
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
The major changes made to the protocol are summarized in this section. Other minor changes 
are incorporated directly into the protocol. The major changes , outlined in Section 6, include 
the following: 
MRI  frequency  changed from annuall y to one at EOS
Clinical laboratory  collection changed from a biennial to annual collection , with urine 
pregnancy  tests for females being substituted at the visits during which other clinical 
laboratory  testing has been removed .
Additionally  minor administrative changes have been made to either correct or clarif y 
verbiage.
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee ( IECs) and Health Authorities .
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update andsubmit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.
Amendment 7 –August 2013
Amendment rationale
Varicella zoster virus (VZV) antibody  testing and surveillance in patients enrolled in this 
extension, including patients enrolled from core studies prior to implementation of mandatory 
pre-treatment anti-VZV antibody  serology , has been clarified in accordance with the 2013 
Core Data Sheet (CDS) update. The language is reinforced to ensure that previous history  of 
varic ella or varicella vaccination is adequatel y documented by a health care professional and 
wording has been strengthened regarding the need for patients to be tested for antibodies to 
determine prior VZV exposure and to vaccinate if negative.
The title of the study  was changed back to the original version in response to feedback from 
the central ethics committee for [LOCATION_009]. This change indicates that only uncontrolled efficacy 
data are collected in this study , which may be subject to bias, as compared to the more 
rigorous efficacy  data collected in a double -blind randomized study . Furthermore, the title 
clarifies that only  patients with relapsing MS were included in the core studies from which the 
patients in trial D2399 are enrolled. 
Several additional administrative changes were made to clarify  the revised screening 
laboratory  tests and schedule of assessments, which were implemented in Amendment 6.
Reversion of title back to original title will allow French cohort of patients to continue in the 
trialand en sure additional awareness of VZV guidance for all countries.  

[COMPANY_001] Confidential Page 15
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Changes to the protocol
The major changes made to the protocol are summarized in this section. Other minor changes 
are incorporated directl y into the protocol. The major changes include the fol lowing:
Clarified VZV antibod y guidance has been added.
The protocol title has been modified.
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee ( IECs) and Health Authorities .
The changes described in this amended protocol require IRB/IEC approval prior to 
implementati on. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed C onsent that takes into account 
the changes described in this amended protocol .
Amendment 6 –July [ADDRESS_685025] dose monitoring at treatment re-
initiation (since recruitment is completed no treatment initiation per se will occur under this 
protocol). In addition, it removes the country -specific guidelines for German y, as the 
monitoring procedures and safet y assessments mandated in the protocol are deemed 
appropriate for adequately  protecting the safety  of patients with an increased risk of 
cardiovascular problems. However, this amendment clarifies that any additional procedures or 
assessments that may  be required as per local prescribing information must be followed.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions. 
The major changes made to the protocol are summarized in this section. Other minor changes 
are incorporated directl y into the protocol. The major changes include the following: 
Exclusion criteria related to the cardiovascular conditions are updated.
Exclusion of patients taking medications that lower heart rate has been added .
German y country -specific recommendations removed; additional procedures and 
assessments required b y local prescribing infor mation should be followed accordingl y.

[COMPANY_001] Confidential Page 16
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Appendix [ADDRESS_685026] (IRBs)/ 
Independent Ethics Committee (IECs) and Health Authorities. 
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, as the changes herein affect the Informed Consent, sites are 
required to update and subm it for approval a revised Informed Consent that takes into account 
the changes desc ribed in this amended protocol.

[COMPANY_001] Confidential Page 17
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Amendment 5-February  [ADDRESS_685027] a heart rate (HR) of <45 beats per minute (
bpm), new onset second 
degree or higher AV block , or if the HR at [ADDRESS_685028] the patient population.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protoc ol using strike through red font for deletions and red underlined for insertions. 
The major changes made to the protocol are summarized in this section. Other minor changes 
are incorporated directl y into the protocol. The major changes include the following: 
Exclusion criteria related to the cardiovascular conditions are updated.

[COMPANY_001] Confidential Page 18
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Appen dix [ADDRESS_685029] dose of the study  drug is 
updated.
Only  for [LOCATION_013] : Patients requiring first dose monitoring will receive continuous [ADDRESS_685030] (IRBs)/ 
Independent Ethics Committee (IECs) and Health Authorities. 
The changes described in thi s amended protocol require IRB/IEC approval prior to 
implementation. In addition, as the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into account 
the changes describ ed in this amended protocol.
Amendment 4-October [ADDRESS_685031] completed 
CFTY720D2309 /E1 as well as there-enrollment of CFTY720D2399 patients who have 
previously  completed this study  based on the original CFTY720D2399 study  endpoint of local 
approval and reimbursement. Furthermore, this amendment will define additional assessments 
to evaluate the long-term efficacy  offingolimod in phase II and III trial patients. Lastl y, this 
amendment aims to bring the study  schedule of assessments as well as thesafet y monitoring 
guidelines in alignment with the fingolimod prescribing information of major countries where 
the medication has been registered.
As indicated in Amendment 3, patients who were participating in the fingolimod phase II/III 
development program have 2.5 to over 8years of long-term exposure . The patient population 
included in these trials is particularl y suitable for long-term evaluation for several reasons: 
patients have met specific inclusion/exclusion criteria , are well char acterized at baseline, have
awell-documented clinical course throughout their participation in the individual clinical 
trials and include patients who were randomized to placebo or active comparator during their 
core studies . 
Thus, these patients alread y have documented long-term data on the safet y and 
efficacy  of fingolimod treatment, coupled with careful baseline assessments. Maintaining 
these patients in the context of an interventional study  will allow for thecontinued collection 
of rigorous long-term data. Therefore, inaddition to following long-term safet y, this 
amendment adds assessments to obtain additional long-term efficacy data, including 
confirmed relapse data and EDSS -based disability  progression, as well as MRI  assessments 
measuring lesion burden and brain atroph y. 
Contrary  to patients included in the phase II and pi[INVESTIGATOR_454294], patients having 
participated in phase IIIb studies have limited fingolimod exposure in predominantly 
uncontrolled studies of short duration. Since these studies focused on specific safet y 
assessments ,MS baseline characteristics were notas well documented since patient selection 

[COMPANY_001] Confidential Page 19
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
was not based on disease activity  and history  and the clinical course of MS during these short 
trials was not followed based on rigorous efficacy  assessments, such as relapse confirmation, 
blinded EDSS rating, and MRI . Therefore ,these patients will continue to follow the current 
study  endpoint of local approval and reimbursement. The patients who are not eligible for 
reimbursement will b e allowed to remain in this study for an additional 180 day s.  
Phase II/III patients, who met the original study  endpoint in CFTY720D2399 of approval and 
reimbursement for fingolimod in their respective countries will be invited to rejoin this study  
in order to continue participation through 30-Jun-2016 and add to the collection of long-term 
safet y and efficacy data. In addition, patients from the CFTY720D2309 /E1study who may 
not have had the opportunity  to enroll into this study  based on the original stu dy endpoint will 
also be invited to participate in this study  through 30- Jun-2016.
The schedule of assessments , frequency  of visits, and the safet y monitoring guidelines have
been updated to reflect the fingolimod prescribing information of major countries where the 
medication has alread y been approved. A nyadditional assessments required by [CONTACT_527638]. In addition 
efficacy measurements, i.e. MRI  assessments (including brain atrop hy), relapse data, and 
disability  progression, have been added for patients with a documented baseline in order to 
obtain additional long -term efficacy data.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
The major changes made tothe protocol are summarized in this section. Other minor changes 
are incorporated directl y into the protocol. The major changes include the following:
Phase IIIb study patients not eligible for reimbursement can remain in the study  [ADDRESS_685032] fingolimod reimbursement.
Patients from CFTY720D 2309/E1 can enter the trial and phase II/III patients who 
previously  completed this trial can re -enter for long -term follow -
up.
Inclusion/ Exclusion criteria are updated .
First dose monitoring required following interruptions of study  drug of greater than 
14 
consecutive day s; previously , following interruption of 8days or greater .
Optional pulmonary  functi on testing ( PFT) is added .
Skin exams are no longer required; remain as optional .

[COMPANY_001] Confidential Page 20
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
OCT and Ophtha lmic exam frequency  is adjusted .
EDSS certification requirement added for investigators evaluating Phase II/III patients; 
collection of functional EDSS scores added for the Phase II/III patients.
Visit frequency  adjusted to every  6 months, starting with Visit 6 .
MRI  testing added for Phase II/III patients.
Definition of “confirmed relapse s
”is added; the confirmed relapse information is to be 
collected.
Several laboratory  tests are no longer being collected (HbA1c, HI V, hepatitis Band C , 
herpes simplex virus 1 and 2 , and rubeola ).
Changes to contraception requirements and to safety  guidelines for pregnant patients.
Changes to safet y guidelines for patients with elevated liver function tests , diagnosis of 
macular edema orbasal cell carcinoma.
A copy  of this amended protocol will be sent to the Institutional Review Board (IRBs)/ 
Independent Ethics Committee (IECs) and Health Authorities. 
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, as the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into account 
the changes described in this amended protocol.
Amendment 3
-May2011
Amendment rationale
Study  CFTY720D2399 includes patients who previously  participated in the fingolimod phase 
II (D2201) and phase III (D2301, D2302, D2309) studies and their associated extension trials 
(CFTY720D2201E1, CFTY720D2301E1, CFTY720D2302E1, CFTY720D2309E1). In 
addition, patients who have participated in and completed ongoing phase IIIb studies of 
fingolimod are also eligible.  Patients who participated in the phase IIIb trials initiated 
treatment with fingolimod only recentl y. Patients who were participating in the phase II/III 
development program have 2-7 years of continuous exposure and met specific 
inclusion/exclusion criteria and have very well documented 
clinical course over those years. 
These latter patients provide valuable long-term data on safet y and efficacy  of fingolimod 
treatment, coupled with careful baseline assessments.
The rationale of this amendment is to allow further follow -up of those patients who previousl y 
completed the Phase II or III fingolimod clinical development trials in an interventional trial 
setting through 30-Jun- 2016.  In addition, this amendment will allow the re-enrollment of 
those phase II/III patients who have completed participation in one of the phase II/III 
extension studies, who remain on fingolimod therapy  and wish to continue on fingolimod in a 
clinical trial setting.

[COMPANY_001] Confidential Page 21
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Those patients originating from the phase IIIb program will be offered to transit ioninto 
observational studies to collect long-term safety  data in the setting of standard medical 
practice upon approval and reimbursement of fingolimod in the respective country , as 
foreseen in the original version of this protocol.
Changes to the protocol
The changes made throughout the protocol update the study  end for the Phase II/III patients to 
fingolimod registr ation, commerciall y availability  and reimburse ment OR through 30-June-
2016, whichever is l ater. 
Changes to specific sections of the protocol are shown in the track change s version of the 
protocol using 
strike through red font for deletions and red underlined for insertions.
A copy  of this amended protocol will be sent to the Institutional Review Board (IRBs)/ 
Independent Ethics Committee (IECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, as the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into ac count 
the changes described in this amended protocol.
Amendment 2-M arch [ADDRESS_685033] (IRBs)/
Independent Ethics Committee ( IECs) and Health Authorities .

[COMPANY_001] Confidential Page 22
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, as the changes herein affect the Informed Consent, sites in 
Norway  are required to update and submit for approval a revised Informed Consent that takes 
into account the changes described in this amended protocol.
Amendment 1-July  2010
Amendment rationale
The rationale for this amendment in the [LOCATION_006] is to revise the study  endpoint to 31- Dec-2012 
to be in line with the Commission Directive 2005/28/EC and the requirements of the [LOCATION_006]
Health Authorit y.  As the study has not yet started, there is no impact on the patients or the 
study  itself.
The rationale for this amendment in Poland is to revise the study  endpoint to [ADDRESS_685034] 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 

[COMPANY_001] Confidential Page 23
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Protocol sy nopsis
Title of study: 
A single arm, open- label, multicenter study  evaluating the long-term,safety andtolerability of 0.5 mg 
fingolimod (FTY 720) administered orally once daily in patients with relapsing forms ofmultiple 
sclerosis.
Purpose and rationale: 
The purpose of this study  is to collect long-term safety ,tolerabil ity, efficacy ,and health outcome sdata 
in patients who participated in the fingolimod multiple sclerosis clinical development program .
Objectives: 
Primary Objectives:
This study  is designed to evaluate the long-term safety and tolerability of fingolimod 0.5 mg/day in 
patients with MS for the duration of the study .
Secondary Objectives:
This study will also evaluate long-term efficacy of fingolimod 0.5 mg/day in patients with MS, as 
measured by [CONTACT_527639], brain volume (atrophy), T1-(non-enhan ced) and T2-weighted 
lesion volume and MS relapse occurrence in Study Part One .
Population: 
Approximately [ADDRESS_685035] completed ongoing or planned clinical trials in the MS 
development program with fingolimod are expected to be enrolled in >500 centers worldwide. 
Inclusion/Exclusion criteria: 
Inclusion C riteria:
Patients eligible for inclusion in this study have to fulfill allof the following criteria:
1.Written informed consent must be obtained before any assessment is performed.
2.Patients who have completed designated ongoing or planned [COMPANY_001] global clinical trials with 
fingolimod and are unable to obtain fingolimod outside a clinical trial .
Exclusion Criteria:
Patients fulfilling anyof the following criteria are not eligible for inclusion in this study:
1.Premature permanent discontinuation from anyfingolimod study due to:
a.An adverse event or serious adverse event or laboratory abnormality.
b.Conditions leading to permanent study drug discontinuation .
2.Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female 
after c onception and until the termination of gestation, confirmed by a positive hCG laborator y 
test (> 5 mIU/ml).   Patients who temporarily or permanently discontinued from any fingolimod 
study because of pregnancy can be re- enrolled.
3.Women of child- bearing potential, defined as all women physiologically capable of becoming 
pregnant, UNLESS they are using highly  effective contraception during the study and for 2 
months after stoppi[INVESTIGATOR_056]. ‘ Highly effective contraception ’defined a s contraception 
which results in less than 1% unwanted pregnancies when used properly according to the 
label .
      

[COMPANY_001] Confidential Page 24
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
4.Chronic disease of the immune s ystem other than MS which may require immunosuppressive 
treatment.
5.Severe active infection or active chronic infection .
6.Previous treatment with cladribine, c yclophosphamide or mitoxantrone.
7.Treatment with monoclonal antibodies (including Natalizumab) in the past 3 months .
8.Uncontrolled diabetes (HbA1c>9%).
9.Macular edema at Baseline.
10.Any medically unstable conditi on that may  interfere with the patient’s ability to cooperate and 
comply with the study procedures, as assessed by [CONTACT_74079].
11.Any of the following cardiovascular conditions:
a.myocardial infarction within the past 6 months prior to enrollment or current unstable 
ischemic heart disease; 
b.cardiac failure at time of Screening (Class III & IV, according to [LOCATION_001] Heart 
Association Classification) or any severe cardiac disease as determined by [CONTACT_1275] ;
c.patients receiving current treatment with Class Ia or III antiarrhythmic drugs (e.g., 
quinidine, disopy ramide, amiodarone, bretylium, sotalol, ibulitide, azimilide, dofelitide , 
ajmaline, procainamide);
d.second -degree AV block Type II or third-degree AV block or corrected QT cinterval 
450 msec in males or >470 msecin fem ales;
e.sick sinus syndrome or sino -atrial heart block ;
f.uncontrolled hypertension despi[INVESTIGATOR_527617] .
12.Any of the following pulmonary conditions during the previous fingolimod study or observed at 
the enrollment vi sit:
a.severe respi[INVESTIGATOR_13521] y disease or pulmonary fibrosis ;
b.active tuberculosis ;
c.in patients enrolling from studies with regular spi[INVESTIGATOR_038]: reduction of FEV1, FVC 
and/or DLCO below 60% of core study baseline values or if FEV1, FVC and/or DLCO 
at extension study  baseline is the second of two consecutive pulmonary function tests 
with values <80% of core study baseline .
13.Severe liver impairment or chronic liver disease .
14.Positive screening for serological markers for hepatitis A, B, C and E indicating acute or 
chronic infection:
anti-hepatitis A virus IgM,
hepatitis B surface antigen and/or anti -hepatitis B core antigen IgM,
anti-hepatitis C virus IgG or IgM,
anti-hepatitis E virus IgM (if positive IgG: do hepatitis E virus -RNA poly merase chain 
reaction: if negative, patient can be included).
Note: The following patients, assuming they have normal aminotransferase activities, can be 
included in the trial:
those testing positive for hepatitis B surface antibody, indicating hepatitis B immunization -
OR-
those testing positive for anti -hepatitis B core antigen IgG, indicating a cured hepatitis B -
OR-
those testing positive for anti -hepatitis A virus IgG, indicating a cured hepa titis A.
Investigational therapy : 
All patients will receive open- label fingolimod 0.5 mg, taken p.o. once daily.
Study design : 

[COMPANY_001] Confidential Page 25
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
This study uses an open -label, multi -center, single treatment arm design allowing patients participating 
in the fingolimod multiple sclerosis clinical development program to enroll to collect additional long-
term safety , tolerability, efficacy , and health outcome sdata. 
This study has two parts:
Part One, collecting long-term safety, tolerability, efficacy, and health outcomes data through 
approximately 30 -Jun-2016, and 
Part Two*, collecting limited safety data until approximately 30-Jun-2018, in a subset of patients 
participating in Part One, and  other eligible patients from ongoing fingolimod trials (e.g., 
CFTY720D2312).
*Eligibility for Part Two is defined as prior fingolimod study  patients who are unable to obtain 
fingolimod outside a clinical trial.
By [CONTACT_11713] 2016, investigators must determine commercial Gilenya eligibility for all active study  patients 
(i.e., reimbursed for commercial Gilenya).  Patients able to obtain commercial Gilenya will then have 
their End of Study (Part One) visit and exit the study , regardless of their post-study treatment decision 
(i.e., continuing on Gilenya commercially or transitioning to another treatment option).  Patients 
discontinuing or completing the study  at Part One who do not continue on commercial Gilenya must 
return for two follow -up study  visits, 3-months and 6-months post-last dose of fingolimod.  Patients 
who choose to continue on comm ercial Gilenya outside the study  are exempted from the follow -up 
visits.
Patients not eligible for reimbursed, commercial Gilenya will be offered continued study participation in 
Part Two until their scheduled study visit closest to 30-Jun-2018 (+/-30 day visit window), with a 
reduced  assessment schedule (see Table 6-2), for the purpose of collecting additional long-term 
safety  and tolerability data in support of the primary  study objective.  Patients discontinuing or 
completing the study  after entering Part Two who do not continue on commercial Gilenya must return 
for one follow -up study  visit, 3-months post-last dose of fingolimod.  Patients who choose to continue 
on commercial Gilenya outside the study are exempted from the follow -up visit.
Safety as sessments : 
Physical/neurological examination
Vital signs
Laboratory blood evaluations
Eye exam by [CONTACT_35425]
ECG
Ophthalmologic Exam/ Optical coherence tomography (OCT) by [CONTACT_15922], if clinically 
indicated
Skin assessments, if clinically indicated
Pulm onary function testing, if clinically indicated
Efficacy assessments : 
MS Relapse
Expanded Disability Status Scale (EDSS)
Magnetic Resonance Imaging (MRI)
Multiple Sclerosis Functional Composite (MSFC)

[COMPANY_001] Confidential Page 26
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Data analysis : 
Unless otherwise specified, the foll owing pertains to the entire study (Study Parts One and Two).
Long- term safety  will be assessed based on adverse events (AEs), laboratory andvital signs as well 
as other investigations performed when clinically indicated .  Analysis of the safety variables will be 
conducted on the safety set. 
Incident rates (IRs) of adverse events per [ADDRESS_685036] assigned 
fingolimod dose (fingolimod 0.5 mg/day and any dose of fingolimod).
To further evaluate the risk with longer fingolim od exposure duration, IR if adverse events reported 
with different fingolimod exposure durations will be compared.  
In addition, the incidence of adverse events (new or worsened from the long-term extension baseline) 
reported during the long-term extensio n will be summarized by [CONTACT_527640].
The incidence of death, serious adverse events (SAEs), AEs leading to discontinuation, and other 
significant AEs will be summarized separately by [CONTACT_168322].
Laboratory data will be summarized using summary  statistics of raw data and change from baseline 
values. For liver function tests, the frequencies and percentages of patients with elevations of 1, 2, 3, 5, 
and 10 times upper limit of normal will be summarized by [CONTACT_765] (Study  Part One only) .  
Vital sign data will be summarized as descriptive statistics for change from baseline value. The 
incidence rates of notable vital sign abnorma lities will be summarized. 
Summary  statistics for ECG parameters (including pre -dose ECG for patients who have this evaluation 
done) will be summariz ed by [CONTACT_765]. Incidence of abnormal ECGs by [CONTACT_527641].
The incidence of macular edema events will be summarized as frequenc y distributions. The patient 
data listing will also be provided.
Pulm onary function test data (FEV 1, FVC, and DLCO, percentage of predicted value for these three 
variables, and smoking status) will be summarized .
The skin assessment will be summarized based on abnormal findings.
The safety  data will also be summarized by [CONTACT_527642].
The safety  data obtained after discontinuation of the study drug will be summarized.
Descri ptive statistics (along with change from baseline to post -baseline visit, where appropriate) will be 
presented for the following variables: Annual Relapse Rate (ARR), time to relapse (including HR), 
absolute EDSS scores, time to EDSS scores of 4, 6, 7, time to 6-month confirmed disability 
progression, absolute MSFC scores
 

[COMPANY_001] Confidential Page 27
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
1 Introducti on
1.1 Background
Multiple Sclerosis (MS) is a chronic, demyelinating, immune -mediated disease of the central 
nervous system characterized by [CONTACT_527643] (Trapp et 
al 1998, Sospedra et al 2005). Typi[INVESTIGATOR_1306] y recurrent acute epi[INVESTIGATOR_1841] (relapses) of neurological 
symptoms, which are followed by a  complete or partial recovery , can be observed during the 
relapsing remitting multiple sclerosis (RRMS) disease course. Approximately  50% of these 
patients progress to secondary  progressive MS (SPMS) within 10 years, 90% within 25 years. 
Apart from these initially  relapsing forms of MS, 10- 15% of patients present with primary 
progressi ve MS (PPMS), which is characterized by [CONTACT_527644] (Keegan et al 2002 ).
Fingolimod (FTY720) is a new chemical entity  for once daily  oral administration which 
completed phase III development and hasobtain edmarketing authorization in the US, Europe 
and a number of other countries and regions since 2010 . 
Pharmacologicall y, fingolimod targets a novel class of G protein
-coupled receptors (GPCRs) 
which bind the pleiotropic sphingolipid mediator sphingosine 1-phosphate (S1P) and acts in 
large part by [CONTACT_100276]-modulating S1P/S1P receptor responses in the immune and the central 
nervous systems. It causes a reversible sequestration of a proportion of CD4+ and CD8+ 
positive T
-cells and B-cells from blood and spleen into lymph nodes (LNs) and Peyer’s 
patches, apparentl y without affecting many  of the functional properties of these cells. Under 
normal circumstances, T-cells selectively  require S1P1 activation for emigration from the 
thymus, and both T-and B-cells require this receptor for egress from peripheral lymphoid 
organs. FTY720- P (FTY720- phosphate) acts as a super agonist of the S1P1 receptor on 
lymphocy tes, inducing its uncoupling/internalization. The internalization of S1P1 renders 
these cells unresponsive to S1P, depriving them of the obligatory  signal to egress from 
lymphoid organs and recirculate to peripheral inflammatory  tissues. As a consequence, 
autoaggressive T-cells remain trapped in the ly mphoid sy stem, i.e. in the autoantigen -draining 
cervical LNs in experimental autoimmune encephalomy elitis (EAE)/MS, and this reduces 
their recirculation to the CNS and abrogates central inflammation.
In a large active controlled study  (CFTY720D2302, TRANSFORMS) vs. intramuscular 
interferon beta-1a(IFN β-1a i.m.), fingolimod showed a significant reduction in relapse rate 
over the 12-month treatment period and also significantl y improved MRI  findings e .g. 
reduction in markers of inflammatory  activity  in the brain . A significant reduction in the loss 
of brain volume was detected, as compared to IFNb -1a i.m. (Cohen et al. 2010). In a 2-year 
placebo
-controlled study  (CFTY720D2301, FREEDOMS) ,fingolimod demonstrated 
sustained reduction of relapse rate, delay ed disability  progression and demonstrated reduction 
in markers 
of inflammatory  activity  in the brain .As in TRANSFORMS, in FREEDOMS a 
significant reduction in the rate of brain atrophy  was observed as compared to placebo as 
early as 6 months after the initiation of treatment, and consistentl y so at 12 and 24 months 
(Kappos et al. 2010 ).

[COMPANY_001] Confidential Page 28
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
The safet y profile of fingolimod has been well characterized in the MS clinical development
program .As of 29-Feb-2012, the MSclinical trials exposure in global and local studies is 
estimated to be approximately  
16,500 patient -years, reached in more than 10,000 MS patients 
treated with fingolimod in Phase II, III, IIIb, and IV studies and their extensions .  For updated 
exposure and safet y information, please refer to current investigator brochure.
The safet y profile observed in the fingolimod MS clinical development program can be 
summarized as follows:
Theoverall incidence of AEs leading to discontinuation of study  drug was slightly  higher
for the fingolimod 0.5 mg/day (
10.5%) than the placebo group ( 8.7%),andhigher again in
thefingolimod 1.25 mg/day  group (14.1%). The overall incidence of SAEs was 
comparable between fingolimod groups (11. 6% and 10. 5% for 1.25 mg/day and 0.5 
mg/day ,respectivel y) and placebo (1 2.2%)
. 
Specific AEs that were reported more commonl y in MS patients treated with fingolimod 
than placebo included elevation of liver enzy mes, in particular increases in AL T and GGT, 
reduction in white blood cell counts (l ymphocy tes and total WBC), transient brady cardia 
following the post first dose of fingolimod, macular edema, hy pertension, dy spnea, 
bronchi tis, and diarrhea. The AEs most prominently  associated with fingolimod treatment, 
e.g. liver enz yme elevations, brad ycardia, and macular edema appeared to show a dose 
related response. There were no AEs that appeared to be specificall y related to long -term
treatment with fingolimod.
In general, the AE profile of fingolimod in MS patients did not depend on gender, age, or 
previous treatment with disease- modify ing drugs. The only  exception was liver enzy me 
elevations which were more frequent in male patients than in female patients treated with 
fingolimod.
The overall incidence of infections, including serious infections, was similar in the 
fingolimod treatment groups and the comparator arms (interferon or placebo) in both 
completed phase III studies. A slightl y higher frequency of lower respi[INVESTIGATOR_67705] (primaril y bronchitis) was observed in fingolimod treated patients, with 
apparent dose effect. Two fatal infections occurred in the fingolimod 1.25 mg/day  group: 
one case of disseminated varicella -zoster virus in a sero-negative patient receiving 
concomitant high dose steroid therap y for an MS relapse, and one case of herpes simplex 
encephalitis in a patient in whom initiation of acyclovir therap y was delayed by [CONTACT_185883]. 
The current data showed no clear relationship bet ween l ymphocy te count and the 
incidence of infections on fingolimod treatment.   The accumulated data from the MS 
program do not show an association of fingolimod therap y with the development of 
malignancies. Cases of ly mphoma (cutaneous T -cell ly mphoproli ferative disorders or 
diffuse B -cell ly mphoma) were reported in premarketing clinical trials in MS patients 
receiving fingolimod at, or above, the recommended dose of 0.5 mg. Based on the small 
number of reported cases and short duration of exposure, the r elationship to fingolimod 
remains uncertain.
Initiation of fingolimod treatment has been associated with atrio- ventricular conduction 
delay s usually  as first -degree atrio -ventricular blocks (prolonged PR interval on ECG). 
Second- degree atrio -ventricular bl ocks, usuall y Mobitz ty pe I (Wenckebach), have been 
observed in less than 0.5% of patients r eceiving fing olimod 0.5 mg in clinical trials.  The 

[COMPANY_001] Confidential Page 29
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
conduction abnormalities ty pi[INVESTIGATOR_1306] y were transient, asymptomatic, usuall y did not require 
treatment and resolved within the first 24 hours on treatment.   
The use of fingolimod in women who are or may become pregnant should only be 
considered if the potential benefit justifies the potential risk to fetus. Animal studies have 
shown reproductive toxicity  including fetal loss and organ defects, notably  persistent 
truncus arteriosus and ventricular septal defect. Furthermore, the receptor affected by 
[CONTACT_527645] (sphingosine -1-phosphate receptor) is known to be involved in vascular 
formation during embryogenesis. The data available from the use of fingolimod in 
pregnant women are too limited to draw conclusions on safety  of fingolimod in pregnancy . 
Since it will take approximately  [ADDRESS_685037] feed.
The safety  and tolerability  profile did not change over time, as determined in the pooled 
data of the phase II an d III studies and their respective open- label extension studies. I n 
particular, the incidence of malignancies and serious infections did not increase over time.
Further long -term data are however needed to better estimate the incidence of rare or time-
depe ndent adverse events.
The current data showed no significant difference on efficacy between the fingolimod 1.25 
mg/day  and the 0.5 mg/day doses in phase III studies. Fingolimod 0.5 mg/day  was associated 
with an overall more favorable risk/benefit profile than fingolimod 1.25 mg/day . Based on 
these data, the dose of fingolimod chosen for registration and for further clinical development 
is 0.5 mg/day .
In the post-marketing setting, isolated delay ed onset events, including transient asystole and 
the one unexp lained death, have occurred within [ADDRESS_685038] 
been confounded by [CONTACT_527646]/or pre-existing diseases and the relationship 
to fingolimod is uncertain.  Therefore, it is recommended that fingolimod not be initiated in
patients with a history  of cardiovascular or cerebrovascular disease or inthose patients taking
heart -rate lowering medications.  Safety  assessments in this study  specifically  address these 
areas of interest in the safet y and tolerability profi le of fingolimod over the long -term.
1.[ADDRESS_685039] long -term safet y,tolerability , efficacy ,and health 
outcomes data in patients who participat edin the fingolimod multiple sclerosis clinical 
development program .
2 Study  objectives
2.1 Primary  objectives
This study  is designed to evaluate thelong-term safet yand tolerability offingolimod 0.5 
mg/day  in patients with MS for the duration of the study .

[COMPANY_001] Confidential Page 30
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
2.2 Secondary  objectives
This study  will also evaluate long-term efficacy of fingolimod 0.5 mg/day  in patients with MS , 
as measured by [CONTACT_527647], brain volume (atroph y), T1-(non-enhanced) and T2-
weighted lesion volume and MS relapse occurrence in Study  Part One .
[ADDRESS_685040] additional long -term safet y, tolerability , efficacy , and health outcomes data. 
This study  has two parts:
Part One, collecting long -term safety , tolerability , efficacy , and health outcomes data 
through approximately  30-Jun-2016, and 
Part Two
*, collecting limited safet y data until approximately  30-Jun-2018, in a subset of 
patients participating in Part One,and  other eligible patients from ongoing fingolimod 
trials (e.g., CFTY720D2312).
*Eligibility  for Part Two isdefined as prior fingolimod study  patients who are unable to 
obtain fingolimod outside a clinical trial.
By [CONTACT_11713] 2016, investigat orsmust determine commercial Gilen ya eligibility  for all active study  
patients (i.e. , reimbursed for commercial Gileny a).  Patients able to obtain commer cial
Gileny a will then have their End of Study  (Part One) visit and exit the study , regardless of 
their post -study  treatment decision (i.e., continuing on Gilen ya commercially  or transitioning 
to another treatment option).  Patients discontinuing or completing the study  at Part One who 
do not continue on commercial Gilen ya must return for two follow -up study  visits, [ADDRESS_685041] to 30- Jun-2018 (+/ -30 day  
visit window), with a reduced  assessment schedule (see Table 6- 2), for the purpose of 
collecting additional long- term safety  and tolerability  data in support of the primary  study  
objective.  Patients discontinuing or completing the study  after entering Part Two who do not 
continue on commercial Gilenya must return for one follow -up study  visit, 3- months post -last 
dose of fingolimod.  Patients who choose t o continue on commercial Gileny a outside the 
study  are exempted from the follow -up visit.  
Patients enrolling in either part of the study  from blind edstudies will remain blinded to the 
identity  of the treatment in the previous study .  In order to ma intain the blind, the monitoring 

[COMPANY_001] Confidential Page 31
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
immediately  after the first dose of study  drug will be performed b y a blinded first-dose 
administrator. 
3.2 Rationale of study  design
The clinical development program of fingolimod has demonstrated efficacy  and a favorable 
benefit/risk ratio of the fingolimod 0.5 mg/day dose in patients with relapsing -remitting 
multiple sclerosis (RRMS),based on reduction in the annualized relapse rate, the reduction in 
risk for disability  progression, and reduction of inflammatory  activity and brain atrophy in the 
brain as eviden cedby [CONTACT_9268]. The safet y profile of fingolimod has been well characterized in 
comparison to both placebo and a first-line treatm ent active comparator. The specific areas of 
concern in the safet y profile of fingolimod have been identified and are addressed as 
appropriate inthis protocol.
This study  isdesigned to collect long-term safety , tolerability , efficacy and health outcomes
data in eligible patients who participat edin the fingolimod multiple sclerosis clinical 
development program .
An open -label, non-comparative single arm design is considered adequate for this type of 
long-term extension. Neither a placebo
-control can be justified over the long-term nor does 
the logistical burden for patients and study  sites justify  the use of an active comparator arm.
The visit and assessment schedule has been aligned with common medical practice in the care 
for patients with MSand with fingolimod treatment . Based on the assumption that continued 
study  participation means there is a positive benefit -risk paradigm for these patients, Part Two 
of the protocol has been added, offering continued patient participation in a subset of patients 
(those unable to obtain access to/reimbursement for commercial Gilen ya) for an additional 
(approximately ) two years, through June 2018.  This will allow continued fingolimod use 
until countries and investigators can find alternate treatment soluti ons.  
In Study  Part One , safet y and tolerability  data will be collected at regular intervals, in addition 
to EDSS assessments and periodic MRI scans , which will document chronic disease 
progression in terms of physical disability  and brain tissue loss without undue burden on the 
patient. Study  Part Two will collect safet y and tolerability data only.
3.3 Rationale of dose/regimen, duration of treatment
The dose and dosing regimen of fingolimod 0.[ADDRESS_685042] benefit/risk 
ratio and is therefore the proposed dose and regimen in the registration files to the health 
authorities and is the approved dose where fingolimod has been registered .
The duration of treatme nt of a patient in this trial is dependent onwhichstudy  the patient 
participated in previously as well as the availability  of reimbursement for commerciall y 
available fingolimod in the respective country . The end of the study  is planned for 30 June 
2018 (+/-3 months).   Individual patient’s end of treatment visits should occur at their routine 
[ADDRESS_685043] to 30 June 2018 to ensure all patients complete within the 
window for the end of the study .

[COMPANY_001] Confidential Page 32
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Patients participating in this study  will provide clinical data of 7-15 years of exposure, which 
will provide information on the long-term safety, tolerability  and efficacy profile to help in 
therapeutic decision making.
[Only  in the [LOCATION_006] and Poland:  The duration of treatment of a patient in this trial is dependent 
on what study  the patient participated in previously (phase II/III vs. other ) . Phase II/III 
patients will remain in the study  maximally  through 30-Jun- 2016.  Patients, who participated
in any designated global fingolimod MS trial other than phase II/III (e.g. CFTY720D2316, 
CFTY720D2320, etc.), were allowed to remain in the study  untilthe drug wasregistered and 
through approximately  one-year post approval or maximally  through 31
-Dec-12.]
[Only  for Norway : The duration of treatment of a patient in this trial ranfor approximately  12 
months following the completion of the previous fingolimod tri al or maximally  through 01-
Aug-
2012.]
3.4 Rationale for choice of comparator
Not applicable .
3.5 Purpose and timing of interim analy ses/design adaptations
Periodic interim safet y analyses to support regulatory updates may  be warranted .
[ADDRESS_685044] completed ongoing or planned clinical trialsin the 
MS development program with fingolimod are expected to be enrolled in >[ADDRESS_685045] to fulfill allof the following criteria:
1.
Written informed consent must be obtained before any  assessment is performed.
2.Patients who have completed designated ongoing or planned [COMPANY_001] global clinical
trialswith fingolimod and are unable to obtain fingolimod outside a clinical trial .
4.2 Exclusion criteria
Patient s fulfilling anyof the following criteria are not eligible for inclusion in this study :
1.Premature permanent discontinuation from anyfingolimod study due to:
a.An adverse event or serious adverse event or laboratory  abnormalit y.
b.Conditions leading to permanent study  drug discontinuation .
2. Pregnant or nursing (lactating) women where pregnancy  is defined as the state of a 
female after conception and until the termination of gestation, confirmed by a positive 

[COMPANY_001] Confidential Page 33
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
hCG laboratory  test (> 5 mI U/ml) .  Patients who temporaril y or permanently 
discontinued from an y fingolimod study because o f pregnancy  or nursing (lactating) 
can be re -enrolled.
3.Women of child
-bearing potential, defined as all women phy siologically  capable of 
becoming pregnant, UNLESS they  are using highly  effective contraception during the 
study  and for 2 months after stoppi[INVESTIGATOR_056] . ‘Highl y effective 
contrac eption ’defined as contraception which result sin less tha n1% unwanted 
pregnancies when used properl y according to the label .    
     Women are considered post - menopausal and not of child- bearing potenti al if they  have 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical 
profile (e.g. age appropriate, history  of vasomotor sy mptoms)  or have had surgical 
bilateral oophorectomy  (with or without hy sterectomy ) or tubal ligation at least six 
weeks prior to baseline. In the case of oophorectomy  alone, onl y when the 
reproductive status of the woman has been confirmed by  [CONTACT_5347].
4. Chronic disease of the immune system other than MS which may  require 
immunosuppressive treatment.  
5.Severe active infect ionor active chronic infection
.
6.Previous treatment with cladribine, cy clophosphamide or mitoxantrone .
7. Treatment with monoclonal antibodies (including Natalizumab) in the past 3 months.
8.
Uncontrolled diabetes (HbA1c>9%).
9.Macular edema at Baseline .
10.Any medicall y unstable condition that may interfere with the patient’s ability  to 
cooperate and comply  with the study  procedures, as assessed b y the treating ph ysician.
11.Any of the following cardiovascular conditions:
a.myocardial infarction within the past 6 months prior to enrollment or current 
unstable ischemic heart disease; 
b.cardiac failure at time of Screening (Class III & IV , according to [LOCATION_001] Heart 
Association Classification) or an y severe cardiac disease as determined b y the 
investigator;
c.patients receiving current treatment with Class Ia and III antiarrhy thmic drugs ( e.g., 
quinidine, disopy ramide, amiodaro ne, bret ylium, sotalol, ibulitide, azimilide, 
dofelitide , ajmaline, procainamide );
d.second -degree AV block Ty pe II or 
third -degree AV block or corrected QT c
interval 450 msec in males or >470 msecin females ;
e.sick sinus sy ndrome or sino- atrial heart block ;
f.uncontrolled h ypertension despi[INVESTIGATOR_527617].
12.Any of the following pulmonary  conditions during the previous fingolimod study or 
observed at enrollment visit:
a.severe respi[INVESTIGATOR_527618] ;
b. a ctive tuberculosis;
c.in patients enrolling from studies with regular spi[INVESTIGATOR_038] : reduction of FEV 1, FVC 
and/or D LCO below 60% of core study  baseline values or if FEV 1, FVC and/or 

[COMPANY_001] Confidential Page 34
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
DLCO at extension study baseline is the second of two conse cutive pulmonary  
function tests with values <80% of core study  baseline .
13.Severe liver impairment or chronic liver disease.
14. P ositive screening for serological markers for hepatitis A, B, C, and E indicating acute 
or chronic infection: 
anti-hepatitis A virus IgM, 
hepatitis B surface antigen and/or anti-hepatitis B core antigen IgM, 
anti-hepatitis C virus IgG or IgM, 
anti-hepatitis E virus IgM ( if positive IgG: do hepatitis E virus -RNA polymerase 
chain reaction; if negative, patient can be included).
Note: The fol lowing patients, assuming they  have normal aminotransferase activities, can 
be included in the trial:
those testing positive for hepatitis B surface antibody , indicating hepatitis B 
immunization -OR-
those testing positive for anti- hepatitis B core antigen IgG, indicating a cured 
hepatitis B -OR-
those testing positive for anti- hepatitis A virus IgG, indicating a cured hepatitis A .
5 Treatment
5.1 Investigational and control treatment
Open -label fingolimod 0.5 mg, taken p.o once daily .
Medication labels will com ply with the legal requirements of each country  and will be printed 
in the local language.  
5.2 Treatment arms
All p atient s will receive open -label fingolimod 0.5 mg, taken p.o. once daily .
5.3 Treatment assignment
There is onl y one treatment arm in this trial which is open -label fingolimod 0.5 mg, taken p.o. 
once dail y.
5.4 Treatment blinding
As this trial is open -label single arm trial, treatment will not be blinded during the course of 
the study .
5.5 Treating the patient
5.5.1 Patient numbering
Each patient is uniquely  identified in the study  by a c ombination of his/her center number and 
patient number. The center number is assigned by [CONTACT_5359]. Upon 

[COMPANY_001] Confidential Page 35
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
signing the informed consent form, the patient is assigned a patient number by  [CONTACT_093].
At each site, the first patient is assigned patient number 1, and subsequent patient s are 
assigned consecutive numbers (e.g. the second patient is assigned patient number 2, the third
patient is assigned patient number 3). The investigator or his/her staff will contact [CONTACT_527648] . 
 Theassigned patient number should be entered in the field labeled “Patient
ID” on the EDC data entry  screen (e.g. enter ‘1’, ‘2’, etc.)  Once assigned to a patient, the 
patient number will not be reused.  If the patient fails to participate for any reason, the IRT 
system must be notified within 2 days that the patient was notenrolled .  Thereason for not 
being enrolled will be entered in the source documents.
5.5.2 Dispensing the study treatment
Each study  site will be supplied by [CONTACT_527649].
The study  drug packaging has a 2-part label. A unique medication number is printed on each 
part of this label.  Investigator staff will identify  the study  drug package(s) to dispense to the 
patient by [CONTACT_527650](s). Immediatel y 
before dispensi ng the package to the patient, investigator staff will detach the tear-off portion 
of the label from the packaging and affix it to the source document (Drug Label Form) for that 
patient’s unique patient number and if applicabl e, logged in the IRT system drug 
accountabilit y web -
based portal.
5.5.[ADDRESS_685046] of the shipment and dispensing of study 
drug in a drug accountability  ledger. Monitoring of drug accountabilit y will be perform ed by 
[CONTACT_527651]. Patients will be asked to 
return all unused study  drug and packaging at each visit, and at the end of the study ,or at the 
time of study  drug discontinuation. 
At the conclusion of the study , and as appropriate during the course of the study , the 
investigator will return all used and unused study drug, packaging, drug labels, and a copy of 
the completed drug accountability  ledger to the [COMPANY_001] monitor or to the [COMPANY_001] address
provided in the investigator folder at each site.

[COMPANY_001] Confidential Page 36
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
5.5.4 Instructions for prescribing and taking study treatment
Study  medication will be dispensed at the Baseline visit and each subsequent treatment visit 
thereafter as per the schedule of assessments.  The patients will receive up to6 bottles of oral 
medication containing 35 capsules per bottle at each visit, which will provide enough 
medication through their next regularl y scheduled visit .
The investigator should promote compliance by [CONTACT_105249]’s safet y and 
the validity  of the study . The patient should be instructed to contact [CONTACT_087]/she 
is unable for any reason to take the stu dy drug as prescribed.  Instruction should also be given 
to the patient to open and use one bottle at a time.  All unused medication as well as empt y 
bottles should be returned to the investigator at the next regularl y scheduled visit.
Study  medication should be taken once a day, preferabl y at the same time every  day, with or 
without food. 
Once the eligibility  of a patient for entry  into the study has been confirmed based on the study 
inclusion/exclusion criteria, study  medication will be dispensed via the IRT system (see 
Section 5.5.2).
Patients enrolling directly from a blinded stud y in which a blinded comparator arm exists 
(placebo or active comparator) may require blinded first do
se observation, performed b y a 
blinded first -dose administrator who cannot discuss the findings with the patients or any one 
else associated with the clinical trial unless this is required for a medical reason.
If patients transition into this extension st udy from the comparator arm of an open -label 
controlled study , the first dose of the study  drug (capsules) administered at the Baseline visit
in this study  must be administered in the clinic under the supervision of the investigator or 
designee , or in acco rdance with the local label.
Similarly , any  patient who re -initiates fingolimod treatment after an interruption, t he first dose 
of the stud y drug (capsules) administered at treatment re -initiation must be administered in the 
clinic under the supervision of the investigator or designee , or in accordance with the local 
label if the following circumstances appl y:
The treatment lasted for 14 day s or less and was interrupted for 1 day  or more, or
The treatment lasted for more than 14 days and less than 29 daysand was interrupted 
for more than 7 consecutive day s, or
The treatment lasted for [ADDRESS_685047] should be sought and overnight monitoring with continuous ECG 
is required under the following circumstances:
The pre -dose ECG shows a QTc interval >470 msec (females) or >450 msec (males) or a 
second degree or higher AV block
The patient has relevant risk factors for QT prolongation, for example, hypokalaemia or 
hypomagnesemia, sick- sinus sy ndrome, or sino -atrial heart block

[COMPANY_001] Confidential Page 37
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
The patient has known ischemic heart disease, history  of m yocardial infarction, congestive 
heart failure, history  of cardiac arrest, cerebrovascular disease, uncontrolled hypertension 
or severe untreated sleep apnea period
The patient has a history  of recurrent s yncope or symptomatic brad ycardia
The resting heart rate pre -dose is <45
For patients receiving (at treatment re-initiation) beta blockers, heart -rate slowing calcium 
channel blocke rs (e.g. ivadrabine, verapamil, or diltiazem), or other substances which may 
decrease heart rate such as digoxin, anticholinesteratic agents or pi[INVESTIGATOR_1227], advice from a 
cardiologist should be sought regarding the switch to non-heart -rate lowering medicin al 
products prior to re-initiating treatment. If a switch to non-heart rate lowering drugs is not 
possible, patients have to be observed overnight. 
Patients transferring from blinded placebo
-controlled or active comparator trials,or patients
enrolling into the study who have been off fingolimod treatment for [ADDRESS_685048] dose ( seeTable 6 -1and 6-2).
Patients requiring first dose monitoring should receive the first dose of study  drug at the study 
center at a time which will allow for the required [ADDRESS_685049] six-
hours thereafter. The patient may be
discharged if specific discharge criteria (outlined inAppendix 4)are met. Hourly  monitoring 
will be extended until findings have resolved if the discharge criteria are not met and should 
pharmacologic intervention be re quired during first -dose observation, overnight monitoring in 
a medical facili ty should be instituted and the first-dose monitoring procedures should be 
repeated upon the 2nddose (see Appendix 4for Guidance for monitoring of patients taking 
their first dose of the study  drug). 
All medication prescribed and dispensed to the patient and all dose interruptions during the 
study  must be recorded on the Do
sage Administration Record eCRF.
All drug kits assigned b y the I RT s ystemwill be recorded in the IRT s ystem.
5.5.[ADDRESS_685050] eCRF .
Absolute lymphocy tecount <0.2x109/l, if confirmed, should lead to treatment interruption 
until recovery . (See Appendix 5for safety  monitoring guidelines).  Should the patient 
interrupt study  drug, and the Investigator decide to re-initiate treatment with study  drug, the 
first-dose monitoring procedure may be required for the restart of study  drug (see Appendix 4
for details).

[COMPANY_001] Confidential Page 38
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
5.5.[ADDRESS_685051] been taken during any 
gap between the completion of the prior study  and enrollment into this extension study  should 
also be recorded, even if the medication is not ongoing at the time of enrollment.  Medications 
that were recorded during the previous study  and had a recorded end prior to completion of 
the previous study  do not need to be re-recorded in this study . Both the start date and the end 
date for each medication should be captured on the “the “Concomitant 
Medications/Significant Non
-Drug Therapi[INVESTIGATOR_527619] ,
as applicable. Use of the following treatments isallowed to manage potential adverse 
reactions associated with the study  drug:
anticholinergics (atropi[INVESTIGATOR_050] s.c. or i.v.) for treatment of sy mptomatic brady cardia as the first 
line treatment, up to 3 mg/day ;
beta-agonists/sy mpathomimetics (dopamine drip 5 -20µg/kg/min or epi[INVESTIGATOR_207368] 2-10 
µg/min) for treatment of non- responsive brad ycardia.
For more recommendations for management of brady cardia, refer to Appendix [ADDRESS_685052] short course of intravenous corticosteroids (
3-5 days of up to 1,000 mg 
methy lprednisolone /day) on an inpatient or outpatient basis is recommended for the treatment 
of relapses if clinicall y warranted (standard of care procedures should be followed during 
treatment) and should be recorded on the Steroid treatment of MS relapses eCRF.   
Taperin g 
with oral corticosteroids is not recommended.
The investigator should instruct the patient to notify  the study  site about any  new medications 
he/she takes after the start of the study  drug. All medications and significant non-drug 
therapi[INVESTIGATOR_014] (including physical therap y and blood transfusions) administered after the patient 
starts treatment with study  drug must be recorded on the Concomitant medications/Significa nt 
Non-Drug Therapi[INVESTIGATOR_527620] e
CRF.  
Vaccination may be less effective during and for up to two months after treatment with 
fingolimod . 
5.5.8 Prohibited treatment
Use of the following treatments isNOT allowed concomitantly  with the study  drug during the 
course of the study :
Immunosuppressive medication (e.g. cyclosporine, azathioprine, methotrexate, 
cyclophosphamide, mitoxantrone, cladribine);
Other concomitant medications: immunoglobulins, monoclonal antibodies, 
adrenocorticot ropic hormone (ACTH -other than if used as a short course (e.g. less than 1 
week) for the treatment of MS relapse) ;
Medications used to treat MS, which may  include glatiramer acetate (Copaxone®), 
interferon β -1a i.m. (Avonex®), interferon β -1a s.c. (Rebif®), interferon β -1b 

[COMPANY_001] Confidential Page 39
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
(Betaseron®/Betaferon®), natalizumab (Tysabri®), azathioprine, methotrexate or any  
other medications used as MS -disease -modify ing agents;
Class I a (e.g. quinidine, disopy ramide) or class III (e.g. amiodarone, sotalol )
antiarrh ythmics . 
The administration of any live or live attenuated vaccine (including for measles) should be 
avoided while patients are receiving study  drug and for 2 months after study  drug 
discontinuation. Following Varicella zoster virus (VZV )vaccination, the initiatio n of study 
drug should be postponed by [ADDRESS_685053] make every  effort to 
determine the primary  reason for a patient’s premature withdrawal from the study  and record 
this information on the appropri ate eCRF.
Study  drug must be discontinued for a given patient if the investigator determines that 
continuing it would result in a significant risk for that patient. In addition, study  drug must be 
discontinued based on results of safety  monitoring as outlined inAppendix 5:  Guidance on 
safet y monitoring and Appendix 7:  Guidance for Ophthalmic Monitoring .The following 
conditions/events may be considered sufficient to support a decision about the study  drug 
discontinuation in individual cases:
serious adverse event (e.g. cardiac failure, diagnosed malignancy ,
new neurological 
symptoms accompanied by  [CONTACT_527652] )abnormal laboratory  
value(s) or abnormal test result(s) (e.g ophthalmic findings). 
withdrawal of consent 
pregnancy (please see Section 6.5.8 andSection 7.3)
use of prohibite d medications, listed in Section 4.2 andSection 5.5.8.
adverse events
protocol deviation
unsatisfactory  therapeutic effect
patient’s condition no longer requires stud y treatment
administrative problems (e.g. patient’s non -compliance)
discontinuation warranted as per local label requirements

[COMPANY_001] Confidential Page 40
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
In addition to scheduled visits, patients who discontinue study  drug due to adverse events or 
abnormalities on safet y monitoring tests must be followed up with additional visits as needed 
in order to confirm the resolution of abnormalities. 
Document the date and primary  reason for stoppi[INVESTIGATOR_527621] e CRF.  If stud y medication i s restarted as per protocol, the reason for the interruption of 
treatment anddate of interruption should be appropriatel y documented in the source 
documents as well as in the Dosage Administration eCRF. 
For patients who are lost to follow -up (i.e. those patients whose status is unclear because they 
fail to appear for study  visits without stating an intention to withdraw), the investigator should 
show "due diligence" by [CONTACT_187888], e.g. dates of t elephone calls, registered letters, etc.
If a patient permanently  discontinues from study  drug, the inves tigator must also contact [CONTACT_21436] s ystem to register the patient’s discontinuation from study  drug. 
Patients who are prematurel y withdrawn from the study will not be replaced by [CONTACT_527653] y enrolled patients.
5.5.[ADDRESS_685054] -study treatment
Study  Part One completion is planned for 30 Jun 2016.  Individual patient’s end of treatment 
visits should occur at their routine [ADDRESS_685055] to 30 June 2016 to ensure 
all patients complete within the window for the end of Study  Part One.
The end of the study  (completion of Study  Part Two) is planned for 30 June 2018.   I ndividual 
patient’s end of treatment visits should occur at their routine [ADDRESS_685056] refer them back to their referring physician for 
appropriate care. 
5.5.12 Early  study termination
The study  can be terminated at any  time for any  reas on by  [CONTACT_5343]
.Should this be necessary , 
the patient should be seen as soon as possible and treated as described in Section 5.5.9 for a 
prematurel y withdrawn patient . The investigator may be informed of additional procedures to 
be followed in order toensure that adequate consideration is given to the protection of the 
patient ’s interests. The investigator will be responsible for informing IRBsand/or ECs of the 
early termination of the trial.
[ADDRESS_685057] all assessments ,and indicates with an “X” the visits when they are 
performed and recorded in the clinical database, with an “S” indicates when aperformed

[COMPANY_001] Confidential Page 41
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
assessment is to be recorded on source documentation, and an “S1” indicates that source 
documentation should be present to confirm the procedure was performed as part of the 
previous fingolimod trial (Specific to the Baseline visit only).If an “S1” procedure was not 
performed inthe previous trial, it has to be performed at Baseline. Assessments performed at 
the final visit of the previous fingolimod trial can fulfill therequir ements of the Baseline only 
if they  are completed within 14 day s ofenrollment in CFTY720D2399.
Patients should follow as much as possible the visit schedule with an allowed “visit window” 
of + 5 daysfor bi-weekly  visits, of + 10 daysfor monthly  visits, of + 14 daysfor quarterl y 
visits and of +30 day s for bi -annual visits .  Ifa visit was performed outside the visit window ,
any subsequent visits should be performed according to the original visit schedule.  In the 
study , one month is defined as 30 cale ndar day s.
Upon availability  of the locally  approved prescribing information, completion of any
additional assessments required by [CONTACT_527654]. The assessments should be completed for all patient s, unless prohibited by [CONTACT_13125]. Any findings qualify ingas AEs/SAEs should be reported as such.
Table 6-1 Assessment schedule (Study  Part One )
Visit No.*Base 
line V1V1121V2 V3 V4 V5 V6 V7...Study 
Completion 
or 
Premature 
Dis-
continuation*
*FU   
114FU
214
Study monthDay 
1Month 
1Month 
3Month 
6Month 
9Month       
12Month 
18Every 6 
Months 
until SC
Informed 
consentXS
Demography S1
Inclusion/ 
exclusion 
criteriaXS
Previous 
Study DetailsXS
Amendment [ADDRESS_685058] the signature [CONTACT_527686] 8 patients informed consent 
Medical history S1
Concomitant 
medsXS XS XS XS XS XS XS XS XS XS XS
Pregnancy 
test15 S1 XS XS XS XS XS XS XS XS XS XS
Physical /neuro
logical examS1 S S S S S S S S S
MRI2XS2aXS

[COMPANY_001] Confidential Page 42
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Visit No.*Base 
line V1V1121V2 V3 V4 V5 V6 V7...Study 
Completion 
or 
Premature 
Dis-
continuation*
*FU   
114FU
[ADDRESS_685059] /Ophthal
mic ExamXS5aXS5aRecord as needed
PFTs3
Record as needed
Vital signsS1 XS XS XS XS XS XS XS XS XS XS
Screening for 
hepatitis A, B, 
C & E and 
uncontrolled 
diabetesXS
Hematology/ S1 XS XS XS XS XS XS XS XS XS XS
Blood 
ChemistryS1 XS XS XS XS XS 1/year XS XS XS
Serology6XS
Dispense 
study drugS S S S S S S
Collect unused 
study drugS S S S S S S
First dose 
monitoring7 XS Record as needed
First Dose 
ECG8 S1 Record as needed
Dosage 
Administration 
RecordXS XS XS XS XS XS XS XS
EDSS12S1 XS XS XS XS XS XS XS
MSFC9S1 XS XS XS XS XS XS XS

[COMPANY_001] Confidential Page 43
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Visit No.*Base 
line V1V1121V2 V3 V4 V5 V6 V7...Study 
Completion 
or 
Premature 
Dis-
continuation*
*FU   
114FU
214
Study monthDay 
1Month 
1Month 
3Month 
6Month 
9Month       
12Month 
18Every 6 
Months 
until SC
MS relapse XS XS XS XS XS XS XS XS XS XS XS
Steroid Use XS XS XS XS XS XS XS XS XS XS XS
Adverse 
events/ SAEsXS XS XS XS XS XS XS XS XS XS XS
Study 
CompletionXS
1.  Visit 112 is only applicable for those patients rolling into this trial from any blinded study which has 
comparator treatment arms (placebo, or active comparator, e.g. study CFTY720D2309) or for any patient who 
has been off fingolimod treatment for 90 days or greater.  All other patients will enroll at Baseline -V1 and come 
in 3 months later for V2.
2.  MRIs are required only for patients from phase II/III trials who had MRI assessments in prior FTY trials. Such 
patients will have the first MRI at V5.  If a patient has already had V5 by [CONTACT_527655] [ADDRESS_685060] -Amendment 8 approvals, 
only the Study Completion MRI is required.
2a. Phase II/III patients that enroll /re-enroll into this study under Amendment 8must have an MRI at the 
Baseline -V1 visit for new patients or at the re- enrollment visit for re -enrolled patients.     
3.  Pulmonary function testing (FEV1, FVC, D LCO) will be performed if clinically indicated.                                     
4.  A quali fied physician includes either a dermatologist or a physician who has participated in a licensed training 
program. Record if performed.
5.  An eye exam will be performed by [CONTACT_1963].
5a.  A 3-month and [ADDRESS_685061] on any patient 
who is rolling into this trial from any blinded study which has comparator treatment arms (placebo or active 
comparator, e.g. study CFTY720D2309) or for any patient who has been off fingolimod treatment for 90 days or 
greater. Then, to be recorded if performed.
6.  Serology testing (if not already performed in the previous fingolimod study) will be performed at the Baseline -
V1 visit to measure Varicella -zoster virus IgG antibodies.
7.  Patients enrolling direct ly from a blinded study may require blinded first -dose observation.  First-dose 
monitoring to be done on any patient who is rolling into this trial from any blinded study which has comparator 
treatment arms (placebo or active comparator, e.g. study CFTY720 D2309) or enrolling from the comparator arm 
of an open -label controlled study or for any patient who has been off fingolimod treatment for the durations
outlined in Appendix 4.
8. First dose 12 lead ECGs (pre- and [ADDRESS_685062]-dose) to be obtained only fo r those patients rolling into this 
trial from any blinded study which has comparator treatment arms (placebo) or for any patient who re-initiates 
fingolimod after having been off fingolimod treatment for the durations outlined in Appendix 4. .   
9.  The MSFC will only be done in patients who had previous MSFC assessments in their previous fingolimod 
study.
 

[COMPANY_001] Confidential Page 44
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Visit No.*Base 
line V1V1121V2 V3 V4 V5 V6 V7...Study 
Completion 
or 
Premature 
Dis-
continuation*
*FU   
114FU
214
Study monthDay 
1Month 
1Month 
3Month 
6Month 
9Month       
12Month 
18Every 6 
Months 
until SC
 
12.  For patients who previously participated in phase II/III trials only (CFTY720D2201/E1, CFTY720D2301/E1, 
CFTY720D2302/E1, CFTY720D2309/E1, etc), EDSS will be assessed by a certified treating Physician (all phase 
II/III investigators and any new raters who join during the study will be required to provide one -time proof of 
Neurostatus EDSS certification). Physicians assessing EDSS for patients from phase IIIb trials do not have to be 
certified, and individual functional scores are not required.                                                                                                                                         
 
 
 
  
 
14.  Follow up visit s(FU) should be scheduled 3 months and 6 months (+/- 14 days) after the last dose of study 
medication.  The follow -up visit s should be done only on patients who have stopped the study but do not 
continue onto fingolimod, either in a study or non -study setting .
15.Serum pregnancy tests are collected at visits where chemistry is collected.  At other visits, urine pregnancy 
tests will be performed on -site with kits provided by [CONTACT_6626]. 
* At each visit the patient m ust be reminded of the importance of remaining vigilant for infections and, in women 
of child -bearing age, practicing contraception per protocol.
** The Study Completion (SC) assessments to be performed if a patient has prematurely discontinued or if 
completed the study per protocol.  For active patients, Study Completion assessments will be performed when 
the patient reaches [ADDRESS_685063].
Table 6-2 Assessment schedule ( Study Part T wo)
Visit No.*Visit 
201A1Visit 
201B2Visit 
2112Visit 
2122Visit 
202Visit 
203Visit 
204…Study 
Comp
letion 
or 
Prem
ature 
DC9FU310
Study month Day11Day12
(First 
Dose 
Monitor)Month 
12Month 
32Month 
+6/6Month 
+12/12Every 6 
Months 
until SC
Informed 
consent3 XS XS
Demography3S1 S1
Inclusion/ 
exclusion criteriaXS XS
Previous Study XS XS

[COMPANY_001] Confidential Page 45
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Details3
Medical History3S1 S1
Concomitant 
medsXS XS XS XS XS XS XS XS XS
Physical/ 
neurological 
examS1 S1 S S S S S S S
Skin exam by a 
qualified 
physician4Record in source as needed
Eye Exam5S1 S1 S S
OCT/Ophthalmic 
ExamS6S6
PFTs Record in source as needed
Vital signs S1 S1 XS XS XS XS XS XS XS
Hematology/ 
Chemistry/ 
Pregnancy7S S S S S S S
Dispense study 
drugS S S S S S
Collect unused 
study drugS S S S S S
First dose 
monitoring8 XS Record as needed
First Dose ECG8XS
Dosage 
Administration 
RecordXS XS XS XS XS XS XS
MS relapse XS XS XS XS XS XS XS XS XS
Steroid Use XS XS XS XS XS XS XS XS XS
Adverse events/ 
SAEsXS XS XS XS XS XS XS XS XS
Study Completion XS
1.  Visit 201A is applicable for current patients or those transitioning from another open -label fingolimod study
2.  Visits 201B , 211 and 212 are applicable only for those patients transitioning from a blinded fingolimod study 
which has comparator treatment arms (placebo, or active comparator, e.g. study CFTY720D2312) , from the 
comparator arm of an unblinded fingolimod study, or for patients who have interrupted treatment for durations as 
outlined in Appendix 4 .  
3. Informed consent, demography, previous study details, and medical history are only applicable if the patient 
enters Study Part Two from another study (i.e., not applicable for patients transitioning from Study Part One). 
4.  A  q ualified physician includes a dermatologist OR a physician who has participated in a licens ed training 
program. 
5.  To be performed by [CONTACT_1963].
6.  A 3-month and [ADDRESS_685064] forpatient swho enroll into this trial from 
any blinded study which has comparator treatment arms (placebo or active comparator, e.g. study 

[COMPANY_001] Confidential Page 46
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
CFTY720D23 12) ORfor any patient who has been off fingolimod treatment for 90 days or greater. Then, to be 
recorded if performed .
7.  Tests will be analyzed locally ; results will not be recorded in the eCRF, but will remain as source 
documentation for ongoing safety assessment (clinically significant lab abnormalities should be reported as AEs).
8.  First dose 12 lead ECGs (pre -and [ADDRESS_685065] -dose) to be obtained only for those patients transitioning from 
a blinded fingolimod study which has comparator treatment arms (placebo, or active comparator, e.g. study 
CFTY720D2312) , from the comparator arm of an unblinded fingolimod study, or for patients who have interrupted 
treatment for durations as outlined in Appendix 4 .
9.  The Study Completion (SC) assessments to be performed if a patient has prematurely discontinued or if 
completed the study per protocol.
10.  Extension follow -up visit (EFU) should be scheduled 3 months (+/-14 days) after the last dose of study 
medi cation.  The follow -up visit should be done only for patients who have stopped the study but do not continue 
onto fingolimod, either in a study or non -study setting.
* At each visit the patient must be reminded of the importance of remaining vigilant for infections and, in women of 
child-bearing age, practicing contraception per protocol.
In addition to the above scheduled visits, patients may  have unscheduled visits following an 
onset of MS relapse or for other reasons as necessary . All information s hould be collected per 
Unscheduled Visit e CRFs.
6.1 Patient demographics/other baseline characteristics
Patient demographic and baseline characteristic data were collected from the patient during 
the previous fingolimod study  which included: date of birth, age, sex, race, ethnicit y, pre-
treatments and source of patient referral. Relevant medical history /current medical condition 
data includes data until the start of study  drug. Where possible, diagnos is and not symptoms 
were recorded. These data will be mapped to this dataset from the patient’s previous 
fingolimod study .
The demograph y data collected in this study  
(date of birth and gender )will ensure the patients 
are linked to their previous study  history .
Previous MS history  (including history  of relapses) wasdocumented in the patient’s medical 
chart and/or in documented dialog with the patient’s referring physician. Information relating 
to a patients MS history  was collected during the previous fingolimod study which included : 
date of MSdiagnosis, date of first MS sy mptoms, ey e history  (e.g. optic neuritis, uveitis), MS 
relapse history  and history  of medications used to treat MSand will be transferred directl y 
into the database from the patient’s previous fingolimod study .
The same info
rmation will be collected for any gap between the previous study  (core or 
extension study , e.g. CFTY720D2309 or CFTY720D2309E) and this study .
6.[ADDRESS_685066] accurate information about thepatient’s previous fingolimod study  details,
the following records will be collected at the enrollment visit for each patient: the patient’s 
previous fingolimod study number, center number, and patient number.

[COMPANY_001] Confidential Page 47
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Upon the implementation of Amendment 4, the following information will be collecte d: the 
date of full approval for Amendment 4, whether or not the patient is re-enrolling into this 
study  (defined as a patient who previously  completed CFTY720D2399 based on the original 
study  endpoint who is now re-entering the study  using the originall y assigned patient ID 
number) and the date of re-enrollment. In addition, data will be collected on any potential 
treatment gap during the time a patient may have temporaril y been out of a fingolimod study
andwhether or not the patient went onto commercial ly available medication during the gap, if 
applicable.
6.[ADDRESS_685067] accurate information about the study  drug exposure, the following records 
should be maintained for each patient receiving study  medication: records of study  medication 
dispensed and 
returned, dosages administered and intervals between visits. Appropriate data 
should be transcribed on the Dosage Administration Record (DAR) eCRF. To allow for 
accurate study  reporting, the DAR will be closed at the completion of Study  Part One and a 
new DAR eCRF will be opened in the Study  Part Two .
Compliance will be assessed by [CONTACT_1755]/or study  personnel at each visit using 
capsule counts and information provided by  [CONTACT_102]. A monitor will perform and document 
drug accountability  during site visits and at the end of the study .
6.4 Efficacy
MS relapse activit y and neurological impairment of MS as measured by [CONTACT_527656] (EDSS) , Magnetic Resonance Imaging (MRI) and by [CONTACT_527657] (MSFC) will be obtained in Study  Part One only in order to 
characterize the disease activity over the long term.
6.4.1 MS relapse
General definition of relapse : Appearance of a new neurological abnormality  or worsening of 
previously  stable or improving pre-existing neurological abnormality , separated by [CONTACT_2669] [ADDRESS_685068] 24 hours and occur in the absence of fever (<37.5°C) or infection.
Definition of confirmed relapse (For Study  Part One only): A relapse must be confirmed by 
[CONTACT_527658] (see Section 6.4.2) . It is recommended that this occur within [ADDRESS_685069] half a step (0.5) on the EDSS or an increase of 1 point on two different Functional 
Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cereb ral 
FS). 
A patient should report symptoms indicative of a MS relapse at a scheduled visit or at any 
other time during the study . Patients must be instructed to immediately  contact [CONTACT_527659]/she develops new, reoccurring or worsening neurologica l symptoms. Standard therap y 
with corticosteroids can be used. 
For suspected MS relapses reported by [CONTACT_527660], the 
investigator will determine whether to bring the patient in for an unscheduled visit based on 

[COMPANY_001] Confidential Page 48
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
the patient’s condition and standard of care. For patients who come in for an unscheduled visit 
at the time of the suspected MS relapse, an EDSS evaluation must beperformed to verify  the 
relapse.   Relapse severity will be determined based on relapse EDSS scores.
Upon receiving a report of symptoms indicative of a relapse, the i
nvestigator will assess 
whether the symptoms occur in the presence of fever or infection. If fever or infection can be 
excluded, the investigator will determine whether the patient will come in for an unscheduled 
visit and EDSS evaluation . If fever or infection cannot be excluded, the neurological 
examination will be postponed until the fever or the infection has ceased
, provided that the 
symptoms indicative of a relapse are still present at that time . 
All relapses , confirmed ( Study  Part One only) and unconfirmed, will be recorded on the 
Summary  of MS Relapses eCRF.   Atypi[INVESTIGATOR_527622] , depending on severity  of relapse.
6.4.2 Expanded Disability  Status Scale (EDSS)
EDSS will be determined only during Study  Part One, based on neurological examination at 
scheduled visits according to Table 6-1and in the setting of asuspected MS relapse.
EDSS is a scale for assessing neurologic impairment in MS. It is a two -part sy stem including :
(1) a series of scores in each of eight functional systems, and (2) the EDSS steps (ranging 
from 0 (normal) to 10 (death due to MS). The functional systems are Visual, Brain Stem, 
Pyramidal, Cerebellar, Sensory , Bowel and Bladder, Cerebral and other funct ions. It is 
recommended that fatigue will not be included into the Cerebral score of the EDSS.
For patients coming from phase II/III studies, EDSS will be assessed by a treating physician
who has been EDSS trained.
  A one-time Neurostatus certification isrequired for all 
evaluating physicians who have patients enrolled from phase II/III studies.  Ifa new rater is 
brought on board at anytime throughout the study , proof of
certification of that rater will be 
required at that time before any EDSS assessment s can be done by [CONTACT_527661]. Acertified
backup evaluating physician should be appointed to conduct neurological exam ination ONLY 
when the primary  
evaluating physician is unavailable due to illness, vacation, or travel. 
Blinding of the evalua tors is notrequired in this protocol and the PI [INVESTIGATOR_527623]
. 
For patients who transferred from trialsother than the phase II/III trials, the individual 
functional scores do not need to be collected, and the evaluating physician performing EDSS 
assessments does not have to carry  acertification .
EDSS assessments are detailed inTable 6-1. Refer toAppendi x 8for information on 
Expanded Disability  Status Scale (EDSS).
6.4.3 Magnetic resonance imaging (MRI) 
MRI s were added in Amendment 4, and are required only  during Study  Part One for the phase 
II/III patients who had MRI  assessments in their prior fingolimod trial.  
Until Amendment [ADDRESS_685070] an MRI  recorded at the 

[COMPANY_001] Confidential Page 49
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
nearest MRI  visit (e.g., V7, V9). Upon Amendment 8 approval, the MRI schedule is revised 
to one MRI  at Study  Completion as outlined in Table 6-1.
Any phase II/III patients who newly  enroll or re-enroll into this study  under Amendment [ADDRESS_685071] an MRI at the Baseline
-V1visit for newl y enrolled patients, or at the re-
enrollment visit (re-enrolled patients will enter back into the study  based on where they 
previously  left off when they  completed the study  based on the original endpoint ; for examp le, 
if V3 was the last completed visit, V4 would be where the patient will begin again).
Assessment of disease activity  by [CONTACT_527662]:
T1-weighted h ypointense lesion volume .
T2-weighted new/enlarging h yperintense lesion count and total T2 volume .
Brain volume .
The Investigator will be able to review all MRIs during the study . For analy sis purposes, the 
MRI s will be reviewed and reported by  a central MRI  reader.   
Scanning
All sequences/scans will be performed according to the MRI  manual .
The radiologist and technician from each center will receive an MRI Manual, outlining 
technical implementation, image qualit y requirements and MRI  administrative procedures. 
Each site will be asked to program the MRI scanner that is designated for evalua tion of the 
study  patients andif not done previously  with the same MRI  Central Reader, perform and 
submit a dummy  scan, so-called “dummy  or dry run” to assess the image quality  and to 
evaluate the compatibility  of the electronic data carrier. Once the dummy run has been 
accepted, all the parameter settings for the study  specific MRI sequences must remain 
unchanged for the duration of the study .
Data handling and evaluation
During the study , the quality  of each scan performed will be assessed by [CONTACT_527663]. As 
soon as the scan is received by  [CONTACT_188648], it will be evaluated for quality , 
completeness and adherence to the protocol. Confirmation of MRI qualit y or a description of 
the quality  problems ,if detected ,will be communicated to the site. If scan is incomplete or 
incorrectly  performed, the study  center will be asked to repeat it as soon as possible. After 
completion of the quality check, all scans will be analy zed according to the MRI  protocol. 
6.4.4 Multiple Sclerosis Functional Composite (MSFC)
The MSFC , performed only during Study  Part One ,is a composite measure encompassing the 
major clinical dimensions of arm, leg and cognitive function. The MSFC consists of three 
objective quantitative tests of neurological function: 
Nine hole peg test (arm dimension) measurement: right and left arm scores; metric: time 
in seconds to insert and remove 9 pegs.
Timed 25 foot walk (leg dimension); measurement: a walk of 25 feet; metric: time taken 
in seconds .

[COMPANY_001] Confidential Page 50
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
PASAT -3 min (cognitive function); meas urement: paced auditory  serial addition test, 3 
minute version; metric: number of correct answers .
The PASAT -[ADDRESS_685072] tapes will be provided to the sites in the local language.  
Refer to Appendix 2 for information on Multiple Sclerosis Functional Composite (MSFC).
MSFC will be assessed by a  physician or qualified individual at each siteon patients who 
have conducted the MSFC in their previous fingolimod studies . MSFC assessments are 
detai led inTable 6-1. Refer toAppendix 2for information on Multiple Sclerosis Functional 
Composite (MSFC).
6.4.[ADDRESS_685073] 
outcome efficacy assessments in MS and serve to characterize the patient population included 
in this study  as well as their disease activity  and neurological status over thelong-term in this 
study .
MSFC assessments will be continued in patients who had assessments done in their previous 
fingolimod studies to describe their functional status over the long -term in this study .
6.5 Safet y
Physical/neurological examination
Vital signs
Laboratory blood evaluations
Eye exam by  [CONTACT_35425]
ECG
Ophthalmologic exams / Optical coherence tomograph y (OCT) by [CONTACT_15922], if 
clinically  indicated
Skin assessments , ifclinically  indicated
Pulmonary  function testing
, ifclinically indicated
6.5.1 Physical /neurological examination
A complete physical examination will be performed as described inTable 6-1and6-2,and 
will include an assessment of skin, head and neck, ly mph nodes, breast, heart, lungs, abdomen, 
back ,and comments 
on general appearance. Initial neurological examination will be a part of 
the physical examination. Investigators should ask the patient if they have any new or 
changed skin lesions as part of each physical examination. If skin lesions (suspected to be 
precancerous or cancerous) are identified during the physical examination , refer to Section 
6.5.2. All significant findings present prior to start of thestudy  drughave been reported on 
the Relevant Medical History /Current Medical Conditions eCRF from the patient’s previous 
fingolimod trial. Significant findings made after the start of study  drugin this study which 
meet the definition of an AE must be recorded on the Adverse Event eCRF.

[COMPANY_001] Confidential Page 51
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
6.5.2 Skin assessments
If,during the course of the study , a patient has any  dermatologic findings suspi[INVESTIGATOR_527624] ,or if a skin disorder is diagnos ed,this information should be 
documented on the Dermatologic Examination and /orAdverse Events eCRF s.
6.5.3 Vital signs
Vital signs will be recorded as described in Table 6-1and6 -2. Vital signs will include sitting 
pulse rate, sitting systolic and diastolic blood pressure, oral temperature (degrees Celsius). 
Height and body  weight were collected at the screening visit of the patient’s previous 
fingolimod trial .
Refer to Complete Guidelines for the monitoring of patients taking their first dose of the study  
drug as described in Appendix 4 .
6.5.4 Laboratory  evaluations
Screening labo
ratory  tests and routine blood samples as described in Table 6-1will be 
collected and analyzed by [CONTACT_527664].  During Study  Part Two, 
laboratory  tests will be collected and analy zed by [CONTACT_4145] (i.e., locally , not using a 
central lab).  
For Study  Part One , details regarding collection of samples, shipment of samples, reporting of 
results, lab normal ranges and alerting abnormal values will be supplied to the site before site 
initiation in a study  laboratory  manual. The results of the analy sis will be made available to 
each site by [CONTACT_527665] 48 hours after receipt of the samples by [CONTACT_27681]. Extreme valu es, specified in the “ Criteria for clinically  notable laboratory  values and vital 
signs” are further specified inAppendix 1,which will generate a “phone alert” to the 
investigator. 
For Study  Part 
Two, samples will be collected and reported in accordance with local
laboratory policies.  Lab results will not be recorded in the eCRF, but will remain as source 
documentation for ongoing safet y assessment.
Investigators will be asked to comment on anyabnor malities on the respective lab result page, 
including a notation of the clinical significance of each abnormal finding in the patient’s 
source documents. The laboratory  sheets will be filed with the patient source documents.
Abnormal laboratory  values or test results should be recorded as adverse events only if they 
induce clinical signs or symptoms, are considered clinically  significant or require therapy . 
Abnormal laboratory  values alone should not be recorded on the adverse event eCRF; 
however, any diagnoses (or signs or symptoms ,if a diagnosis is not possible) associated with 
the abnormal findings should be recorded on the adverse event eCRF.
[IP_ADDRESS] Hematology
Hematology  parameters will be collected as described inTable 6-1and 6-2, and will include: 
RBC count, total and differential WBC count (basophils, eosinophils, lymphocy tes, 
monocy tes, neutrophils, WBC segments), platelet count, hemoglobin, hematocrit , MCV, 

[COMPANY_001] Confidential Page 52
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
MCH, MCHC, LUC, RBC morphol ogy. Notable abnormalities are defined in the Criteria for 
clinically  notable laboratory  values and vital signs further specified in Appendix 1 .
 
 
 
[IP_ADDRESS] Clinical Chemist ry
Blood samples will be collected as described inTable 6-1and 6 -2, and will include the 
following parameters: sodium, potassium, chloride, calcium, magnesium, phosphate, blood 
urea nitrogen (BUN), random glucose, albumin, alkaline phosphatase, creatinine, ALT, AST, 
GGT, amylase, total 
bilirubin, conjugated bilirubin, total cholesterol, trigly cerides, HDL and
LDL . Abnormal laboratory  parameters, inconsistent with clinical presentation of MS or 
suspi[INVESTIGATOR_527625], should be repeated for accura cy.    If an increase
of amylase above the clinically  notable value ( ≥300 U/L ) is observed at any subsequent visits , 
a lipase should be tested to determine the origin of elevated amylase (pancreatic versus extra 
pancreatic). Refer to the Guidance on monitoring patients with elevated liver function tests in
Appendix 5 .
It is recommended that patients without a health care professional confirmed history  of 
chickenpox or documentation of a full course of vaccination with varic ella vaccine undergo 
antibody  testing to varicella zoster virus (VZV) before initiating fingolimod. Serology  testing 
will therefore be performed at Baseline for any patient that has not undergone this testing 
during participation in their previous fingolim od trial to determine the patient's immune status 
(IgG antibodies will be measured) for varicella zoster virus. A full course of vaccination for 
antibody -negative patients with varicella vaccine is recommended prior to commencing 
treatment with fingolimod.
Patients who are negative for varicella -zoster virus IgG antibodies at baseline ,and wish to be 
immunized, will need to interrupt study  treatment for [ADDRESS_685074] infection or vaccination. Patients with prior 
infection may be at risk of viral reactivation (e.g. shingles) and should be instructed to inform 
the investigator of any signs or symptoms suggestive of these conditions, so that prompt 
treatment may  be initiated.
Patients will also be tested for uncontrolled diabetes and serological markers for hepatitis A, 
B, C and E indicating acute or chroni c infection at baseline as part of the revised screening 
laboratory  assessments as described in Table 6 -1.
Please refer to the Guidance on monitoring of patients with infections in Appendix 5 .

[COMPANY_001] Confidential Page 53
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
6.5.5 Ophthalmologic exams/ Optical coherence tomography  (OCT)
An eyeexamination will be performed by [CONTACT_527666] 6-1.  
The treating physician should refer the patient to an ophthalmologist for an exam and/or OCT 
if clinically  warranted. An OCT and ophthalmologic exam will be performed by [CONTACT_527667] 3 for any patient rolling into this study  from a blinded study  which 
has comparator treatment arms (placebo or active comparator) and for any patient who has 
been off fingolimod treatment for [ADDRESS_685075]’s 
judgment. Further ophthalmologic evaluations will be conducted until such time as resolution 
is confirmed or no further improvement is expected by [CONTACT_1964] (based on a 
follow -up period of not less than 3 months). If the patient does not show definite signs of 
improvement on examination by [CONTACT_527668] (e.g. OCT) after 6-[ADDRESS_685076] experienced in the managem ent of this condition should be initiated. 
Please refer to the Guidance for Ophthalmic Monitoring Appendix 7for complete guidance 
for patients with diagnosis of macular edema.
6.5.6 Electrocardiogram (ECG)
First dose ECGs will be collected as described inTable 6-1and6-2. Two ECGs are required 
for first-dose monitoring and will be performed for those patients rolling into this trial from a 
blinded 
trial, a trial which has a comparator treatment arm, as well as for any patient who has 
been off fingolimod treatment for the duration outlined in Appendix 4.
The first ECG will be performed prior to the study  drug administration; the second ECG will 
be performed approximately  6-hours post-first dose, prior to the patient being discharged. If 
study  drug treatment is interrupted and treatment re-initiation meets the requirement for 
observation ( SeeAppendix 4 ),the above procedures will be repeated
.
6.5.7 Pulmonary  function tests
Pulmonary  function tests (PFTs) evaluating forced expi[INVESTIGATOR_527626] 1 second (FEV1), 
forced vital capacit y (FVC) and carbon monoxide diffusing capacity (DLCO) will be 
performed ,when clinically  indic ated in the opi[INVESTIGATOR_021] .

[COMPANY_001] Confidential Page 54
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
6.5.8 Pregnancy  and assessments of fertility
Pregnancy  testswill be performed for all women as detailed inTable 6-1and6-2. During 
Study  Part One, visits requiring serum pregnancy tests will be performed by [CONTACT_6626]; 
those visits re quiring urine pregnancy  tests will be performed locally  using a urine dipstick kit 
provided by [CONTACT_6626].  During Study  Part Two, pregnancy  tests will be performed 
locally , serum at visits where blood chemistry  samples are collected, and urine at anyother 
time points.
Patients becoming pregnant must interrupt the study  drug. If patients interrupt treatment 
because of a pregnancy , they can remain in the study  and re-start fingolimod treatment after 
delivery  and discontinuation of nursing.
  Pregnant pa tients continuing in the study  during dose
interruption will need to have regular visits and complete assessments deemed safe for her by 
[CONTACT_079].   Prior to resuming fingolimod therapy and the mandatory  on-site 
first-dose monitoring , patients must have a negative serum pregnancy  test and must no longer 
be nursing
.
6.5.[ADDRESS_685077] been reported at very low frequencies in the 
clinical development program, especiall y with the fingolimod 0.5 mg/day dose treatment .
Therefore, upon initiation of the first dose of fingolimod , there must be a mandatory  on site 
monitor ing for a minimum of 6 hours , with additional monitoring as appropriate; refer to 
Appendix [ADDRESS_685078] scan is foreseen to 
be completed at three and six months after treatment initiation/re -initiation for patients 
meeting this requirement as outlined in Section 5.5.4.
In the fingolimod clinical development program, there is limited experience in multiple 
sclerosis patients with diabetes mellitus. Patients with diabetes me llitus are at increased risk of 
macular edema and may require additional ophthalmologic observation, as determined by [CONTACT_1275].
As dose- dependent reversible reduction was observed in forced expi[INVESTIGATOR_527627] , pulmonary  function testing will be performed, if clinically  indicated.

[COMPANY_001] Confidential Page 55
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399

[COMPANY_001] Confidential Page 56
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399

[COMPANY_001] Confidential Page 57
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
7 Safety  monitoring
7.1 Adverse events
An adverse event is the appearance or worsening of any undesirable sign, symptom, or 
medical condition occurring after starting the study  drug even if the event is not considered to 
be related to study  drug. Study  drug refers to the investigational drug, fingol imod given 
during this study .  Medical conditions/diseases present before starting study  drug are only 
considered adverse events if they worsen after starting study  drug. Abnormal laboratory 
values or test results constitute adverse events only if they induce clinical signs or symptoms, 
are considered clinicall y significant, or require therap y. 
The occurrence of adverse events should be sought by  [CONTACT_105]-directive questioning of the patient 
at each visit during the study . Adverse events also may  be detected wh en they are volunteered 
by [CONTACT_24479], laboratory  test, or 
other assessments. All adverse events must be recorded on the Adverse Event e
CRF pages 
with the following information:
1.the severit y grade (mild, moderate, severe) 
2.its relationship to the study  drug(s) (suspected/not suspected)
3. its duration (start and end dates or if continuing at final exam)
4.whether it constitutes a serious adverse event (SAE)
An SAE is defined as an event which fulfills one or several of the following criteria:
is fatal or life -threatening 
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospi[INVESTIGATOR_1081], unless 
hospi[INVESTIGATOR_062]:
routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition (e.g. hospi[INVESTIGATOR_527628])
elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since the start of study  drug
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063] 
social reasons and respi[INVESTIGATOR_5316]’s 
general condition
is medically  significant, i.e., defined as an event that jeopardizes the patient or may  
require medical or surgical intervention to prevent one of the outcomes listed above
Unlike routine safety assessments, SAEs are monitored continuously and have special 
reporting requirements; see Section 7.2.
All adverse events should be treated appropriately .  Treatment may  include one or more of the 
following: no action taken (i.e., further observation only); study drug temporaril y interrupted; 
study  drug permanently  discontinued due to this adverse event; concomitant medication given; 
non-drug therapy  given; patient hospi[INVESTIGATOR_057]/patient’s hospi[INVESTIGATOR_18533]. Refer to the 

[COMPANY_001] Confidential Page 58
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Guidance on Safet y Monitoring (Appendix 5).The action taken to treat the adverse event 
should be recorded on the Adverse Event eCRF. 
Once an adverse event is detected, it should be followed until its resolution or until it is 
judged to be permanent, and assessment should be made at each visit (or more frequentl y, if 
necessary ) of any changes in severit y, the suspected relationship to the study  drug, the 
interventions required to treat it, and the outcome.
Information about side effects alread y known about the investigational drug can be found in 
the Investigator Brochure (IB) or will be communicated between IB updates in the form of 
Investigator Notifications (Dear Doctor’s letter). This information will be included in the 
patient infor med consent and should be discussed with the patient during the study  as needed.
7.2 Serious adverse event reporting
To ensure patient safet y, every  SAE, regardless of suspected causality , occurring after the 
patient has provided informed consent and until 6 weeks after the patient has stopped study  
participation (defined as time of last dose of study drug taken or last visit whichever is later) 
must be reported to [COMPANY_001] within [ADDRESS_685079] be kept with the case report 
form documentation at the study  site.
Follow -up information is sent to the same person to whom the original SAE Report Form was 
sent, using a new SAE Report Form stating that this is a follow -up to the previously  reported 
SAE and giving the date of the original report. The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated, whether the blind was 
broken or not, and whether the patient continued or withdrew from study  participation. 
If the SAE is not previously  documented in the Investigator’s Brochure and is thought to be 
related to the [COMPANY_001] study  drug, a Drug Safety  and Epi[INVESTIGATOR_527629]. 
[COMPANY_001] may need to issue an Investigator Notification (IN) to inform all investigators 
involved in any study with the same drug that this SAE has been reported. Suspected 
Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to the 

[COMPANY_001] Confidential Page 59
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
competent authorities and relevant ethics committees in accordance with Directive 
2001/20/EC or as per national regulatory  requirements in part icipating countries.
7.[ADDRESS_685080] be reported to 
[COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy  should be followed up 
to determine outcome, including spontaneous or voluntary  termination, details of the birth, 
and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or 
newborn complications.   Pre gnant women should be encouraged to participate in the 
pregnancy  registry to collec t additional safet ydata on this population.
Pregnancy should be recorded on a Clinical Trial Pregnancy  Form and reported by [CONTACT_50105] y and Epi[INVESTIGATOR_18540]. Pregnanc y 
follow -
up should be recorded on the same form and should include an assessment of the 
possible relationship to the [COMPANY_001] study  drug of any pregnancy  outcome. Any SAE 
experienced during pregnancy  must be reported on the SAE Report Form.
8 Data revie w and database management
8.1 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] 
representative will review the protocol and eCRFs with the investigators and their staff. 
During the study , the field monitor will visit the site regularl y to check the completeness of 
patient records, the accuracy  of entries on the eCRFs, the adherence to the protocol and to 
Good Clinical Practice, the progress of enrollment, and to ensure that study  drug is being 
stored, dispensed, and accounted for according to specifications. Key study personnel must be 
available to assist the field monitor during these visits.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All infor mation on eCRFs must be traceable to these source documents in the 
patient ’s file. The investigator must also keep the original informed consent form signed by 
[CONTACT_102] (a signed copy  is given to the patient ).
The investigator must give the monitor access to all relevant source documents to confir m 
their consistency  with the eCRF entries. [COMPANY_001] monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, 
documentation of SAEs, and the recording of data that will be used for all primary  and safet y 
variables. Additional checks of the consistency of the source data with the eCRFs are 
performed according to the study -specific monitoring plan. No information in source 
documents about the identity  of the patient s will be disclosed.

[COMPANY_001] Confidential Page 60
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
8.[ADDRESS_685081], which employ s the Anatomical Therapeutic Chemical classification system. 
Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
Laboratory  samples will be processed centrall y and the results will be sent electronically  to 
the designated CRO (Part One only )
.
MRI  readings will be processed centrall y and the results will be sent electronicall y to the 
designated CRO.
ECGs will be done locally  and the outcomes will be entered into the database.
Data about all study  drug dispensed to the patient and all IRTrecorded information will be 
tracked using an Interactive Response Technology system (IRT). The system will be supplied
by a vendor, who will also manage the database. The database will be sent electronically  to a 
designated CRO.
[ADDRESS_685082] dose of fingolimod in the 
original core/extension studies , if available, and in this long-term follow -up study  will be 
analyzed to evaluate the long-term safet y, tolerability , and effectiveness of fingolimod 0.5 
mg/day  in patients with MS.  The baseline relative to the first dose of fingolimod (FDF 
baseline) will be used where change from baseline is analy zed.  All the summaries will be 
provided by [CONTACT_527669], (i.e., fingolimod 0.5 mg/day) and any dose 
of fingolimod.

[COMPANY_001] Confidential Page 61
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
During Study  Part Two, only adverse events, first dose monitoring, vital signs, 
Ophthalmological exam/OCT, and relapse are collected. The analysis including data from 
Study  Part Two will be specified in the relevant sections.
The follow -updata after discontinuation of the study  treatment in Study  Part One or Study  
Part Two will also 
be summarized where appropriate .
Summary  statistics for continuous variables will include N, mean, standard deviation, 
minimum, lower quartile, median, upper quartile and maximum.
Summary  statistics for discrete variables will be presented in terms of absolute and relative 
frequencies.  AE incidence adjusted by [CONTACT_527670] 100 patient years of 
the at -risk population.
9.1 Analysis sets
Assign ment of patients into the different analysis sets will be performed prior to locking the 
database and beginning the data anal ysis.
Summary  statistics will be provided for patient disposition (completers and premature study  
discontinuations) in this long- term follow -up study .
A table on number and percentage of patients with each protocol deviation in this long-term 
follow -up study will be provided . 
In addition, the number of patients per anal ysis set will be tabulated.
Enrolled set 
The Enrolled set will consist of all patients who were assigned a subject IDin this long-term 
follow -up study .
Safety  set 
The Safet y set will consist of all patients that received at least one dose of study  drug in this 
long-term follow -up study .
Fingolimod safety  set 
The fingolimod safet y set will include all patients who entered the long-term follow up study
and received at least one dose of fingolimod in any study, i.e., in the original core/extension 
MS studies or this long -term follow up study .
Fingolimod Full Analysis Set
The fingolimod full analy sis set (FAS) will include all patients who entered the long-term 
follow-
up study  and received at least one dose of fingolimod in any study, i.e., in the original 
core/extension MS studies or this long -term follow up -study.

[COMPANY_001] Confidential Page 62
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
9.1.[ADDRESS_685083] one 
dose of study  medication after completing S tudy Part One. 
9.2 Patient demographics and other baseline characteristics
Demographic and background information collected from the clinical studies (core & 
extensions) from which the patients are transferred to this long-term extension study  will be 
summarized .  Backgr ound information includes prior MS treatment including previous 
exposure to fingolimod , relevant medical history  / current medical conditions, duration of the 
disease, andbaseline EDSS.   Identification of clinical study  participation prior to transfer int o 
this long-term extension study  will also be provided.  Summaries will be provided based on 
the enrolled set.
9.3 Treatments (study  drug, rescue medication, other concomitant 
therapi[INVESTIGATOR_014], compliance)
Use of concomitant medications in this long-term follow -up study will be listed and 
summarized based on the Safety  set to support the analy sis including data from Study  Part 
One or based on the subgroup of patients who entered Study  Part Two of the Safety  set to 
support the anal yses including data from Study  Part Two.
9.4 Analysis of the primary  variable(s)
9.4.1 Variable
Long -term safet y will be assessed based on adverse events (AEs), laboratory and vital signs as 
well as other investigations performed when clinically  indicated. 
Analy sis of the safety  variables will be con ducted on
Safety set:for an y analyses including data collected during the long -term follow up study  
only
Fingolimod safet y set: for anal yses including data from first dose of fingolimod in the 
original core/extension study , if there is any , and in the long- term follow up study .
Given the nature of the design, the data will be presented using descriptive statistics and no 
inferential analyses are planned.  
[IP_ADDRESS] Adverse events (A Es)
Inciden cerates (IRs) of adverse events per [ADDRESS_685084] 
assigned fingolimod dose (fingolimod 0.5 mg/day  and any dose of fingolimod) based on the 
fingolimod safety  set
.
To further evaluate the risk with longer fingolimod exposure duration, adverse events reported 
with different fingolimod exposure durations will be assessed based on the fingolimod safet y 
set.  

[COMPANY_001] Confidential Page 63
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
In addition, the incidence of adverse events (new or worsened from the long-term extension 
baseline) reported during the long-term follow up study will be summarized by [CONTACT_527671] y set.  
Any adverse events
Serious adverse events (SAEs)
Suspected study  drug related adverse events
Adverse events leading to discontinuation
Deaths
All information pertaining to serious adverse events and deaths noted during th isstudy  will be 
listed by  [CONTACT_527672].
The same analysis including data collected during the Study  Part Two will be conducted for 
the subgroup of patients who entered Study  Part Two .
[IP_ADDRESS] Laboratory
Laboratory  data collected up to the end of Study Part One will be summarized by [CONTACT_527673] ( FDF baseline to most 
extreme post-baseline value ). For liver function tests, the frequencies and percentages of 
patients with elevations of 1, 2, 3, 5, and [ADDRESS_685085] is performed for AE reporting purpose according to local 
policies and no laboratory  data is reported in the clinical data base for anal ysis.
[IP_ADDRESS] Vital signs
Vital sign data collected up to the end of Study  Part One will be summarized as descriptive 
statistics for change from FDF baseline value. The incidence rates of notable vital sign 
abnormalities will be summarized. 
A listing of vital sign data for patients with abnormal findings will be provided.
The same analysis including data collected during the Study  Part Two will be conducted for 
the subgroup of patients who entered Study  Part Two .
[IP_ADDRESS] Electrocardiograms
Analy sis will be performed forfirst dose ECGs during the long- term follow up study  based on 
the safet y set.
Summary  statistics for ECG parameters (including pre-dose ECG for patients who have this 
evaluation done ) will be summarized by [CONTACT_527674]. Incidence of abnormal ECGs
will be presented.
A listing of ECG data for patients with abnormal findings will be provided.

[COMPANY_001] Confidential Page 64
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
The same analysis including data collected during the Study  Part Two will be conducted for 
the subgroup of patients who entered Study  Part Two.
[IP_ADDRESS] Ophthalmic asse ssments
The incidence of macular edema events during Study  Part One will be summarized as 
frequency  distributions based on the safet y set. The patient data listing will also be provided.
During Study  Part Two, ophthalmic assessments will be conducted for safet y monitoring 
purposes at the Month 1 visit and Month 3 visitonly for patients who transitioned from a 
blinded fingolimod study  with comparator treatment arms. The patient is not reported in the 
clinical database for analy sis.
[IP_ADDRESS] Pulmonary  function tests
Pulmonary  function test data (FEV 1, FVC, and DLCO, percentage of predicted value for these 
three variables, and smoking status) collected during Study  Part One will be listed based on
the safet y set.During Study  Part Two, PFT assessment will be con ducted as need for safet y 
monitoring purpose and the patient data is not reported in the clinical database for anal ysis.
[IP_ADDRESS] Skin assessment
The skin assessment sduring Study  Part One will be listed for those who had abnormal 
findings based onthe safety  set.During Study  Part Two, skin assessment will be conducted 
as need for safet y monitoring purpose and the patient data is not reported in the clinical 
database for anal ysis.
9.4.2 Handling of missing values/censoring/discontinuations
Missing values will not be imp uted.
9.4.3 Supportive analy ses
In addition, adverse events will be summarized by [CONTACT_527675], such as:
Duration of fingolimod exposure.
Previous core/extension trials: Phase II/III studies (i.e., D2201, D2301, D2302, and 
D2309) .
The follow -up safet y data after discontinuation of the study  drug will be summarized.
9.[ADDRESS_685086] one dose of fingolimod.

[COMPANY_001] Confidential Page 65
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
[IP_ADDRESS] MS Relapse
Descriptive statistics on the Annual Relapse Rate (ARR) will be presented. ARR (for each 
patient) iscalculated as the total number of relapses divided by  [CONTACT_527676] s on study, 
multiplied by 365.25. The ARR for the whole treatment group is the mean of ARRs from all 
patients in the group. Data on time to relapse will also be summarized.   In addition, model 
based estimates will be obtained by [CONTACT_6486] a negative binomial regression model adjusted for 
the number of relapses in the last two years at core baseline and FDF baseline EDSS score , 
with the logarithm of the duration of the observat ion period as the offset variable.  All the 
analyses will be done for all relapses (confirmed and unconfirmed) and for confirmed relapses.
All MS relapses arecollected during Study  Part Two for safety  monitoring purpose s. Anal ysis 
including any relapse data collected during Study  Part Two will be conducted based on the 
fingolimod safety  setfor the subgroup of patients who entered Study  Part Two.
[IP_ADDRESS] MRI
Descriptive statistics on number of new / newl y enlarging T2 lesions, T2 lesion total volume, 
T1 black hole volume and brain volume (atroph y) for change from previous 
scan and change 
from FDF baseline will be presented by  [CONTACT_527677]. Model 
based estimates will also be provided for the following endpoints: 
New / newly enlarging T2 lesions: the annualized rate of new/newl y enlarging T2 lesions 
will be estimated based on a negative binomial regression model with log -link. The number of 
new / newly enlarging T2 lesions relative to FDF baseline will be used as the response 
variable, and the natural log of the time (in years) of the MRI -assessment from the 
baseline /screening scan will serve as the offset variable to adjust for the various lengths of 
follow -up times between patients. The model will include treatment and baseline volume of 
T2 lesions as continuous covariates.
Brain volume: Percent brain volume change from baseline will be estimated based on a 
mixed effects model with repeated measures and auto- regressive within -subject covariance 
structure of first order will be used with visit, treatment, core baseline normalized brain 
volume, number of Gd-enhancing lesions at FDF baseline, and T2 lesion volume at FDF 
baseline as fixed effects, and individual patient as a random effect. Kenward and Rogers’ 
adjustment for the degrees of freedom will be applied. Annualized rate of brain atroph y 
(ARBA) will also be estimated based on the same mixed effects model.
[IP_ADDRESS] EDSS
Descriptive statistics on absolute EDSS scores (overall and by [INVESTIGATOR_285610]) ,change from FDF
baseline , and count (%) based on EDSS change categories will be presented. The proportion
of patients with 6-month confirmed disability  progression will be presented. Data on time to 
6-month confirmed disability  progression, and EDSS score of 4, 6, 7 will be summarized. 
EDSS will be used for the confirmation of MS relapse and the confirmation of disability  
progression.  Disability  progression in this study is defined as an increase in the EDSS score 
by 1.5 point for patients with an FDF baseline EDSS of 0, 
1 point for patients with an FDF
baseline EDSS of≥1 and ≤5.5, and by 0.5 points for patients with an FDF baseline 
EDSS >5.5, confirmed after 6 months and at all intermediate EDSS assessments.

[COMPANY_001] Confidential Page 66
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
[IP_ADDRESS] MSFC
Descriptive statistics onabsolute MSFC scores and change from FDF baseline will be 
presented for patients who have done this evaluation . 
The MSFC isbased on 3 components (dimensions): leg, arm, and cognitive function and the 
corresponding tests are 25-foot Timed Walk (T25FW), 9-Hole Peg Test (9HPT), and Paced 
Auditory  Serial Addition Test (PASAT3). The scores for these [ADDRESS_685087] formulas will be given in the 
statistical analy sis plan.
9.6 Sample size calculation
Given that this is along-term extension study  with primary  descriptive purpose , no formal 
sample size calculation will be used to determine enrollment in this study .The sample size is 
defined by [CONTACT_527678]/new core/extension trials that meet 
the inclusion and exclusion criteria . It is estimated that about 5000 patients will be enrolled in 
this trial. 

[COMPANY_001] Confidential Page 67
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
9.7 Power for analy sis of key secondary  variables
Not applicable.
9.8 Interim analy ses
Periodic interim safet y analyses to support regulatory  updates and interim reports may be 
warranted.
As this is an open -label, multi- center, single treatment arm long-term safety  and tolerabilit y 
study  without formal h ypothesis tests, there is no relevance on blinding or alpha -adjustment.
10 Ethical considerations
10.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented and reported in accordance with 
the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC, USCode of Federal Regulations Title 
21, and Japanese Ministry  of Health, Labor, and Welfare), and with the ethical principles laid 
down in the Declaration of Helsinki.
10.2 Informed consent procedures
Eligible patient s may only be included in the study  after providing written (witnessed, where 
required by [CONTACT_6617]), IRB/IEC -approved informed consent, or, if incapable of doing 
so, after such consent has been provided by a legally  acceptable representative of the patient . 
In cases where the patient’s repre sentative gives consent, the patient should be informed about 
the study  to the extent possible given his/her understanding. If the patient is capable of doing 
so, he/she should indicate assent by [CONTACT_18684] a separate assent form. Informed consent must be obtained before 
conducting any study -specific procedures (i.e. all of the procedures described in the protocol). 
The process of obtaining informed consent should be documented in the patient
sourc e 
documents. 
[COMPANY_001] will provide to investigators in a separate document a proposed informed consent 
form that complies with the ICH GCP guideline and regulatory  requirements and is 
considered appropriate for this study . Any  changes to the proposed cons ent form suggested by  
[CONTACT_90219]/IEC, and a copy 
of the approved version must be provided to the [COMPANY_001] monitor after IRB/IEC approval.
Women of child bearing potential should be informed that taking the study  drugmay involve 
unknown risks to the fetus if pregnancy  were to occur during the study  and agree that in order 
to participate in the study  they must adhere to the contraception requirement for the duration 
of the study . If there is any question that the patient will not reliably  comply , they should not 
be entered in the study .

[COMPANY_001] Confidential Page 68
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
10.3 Responsibilities of the investigator and IRB/IEC
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/I ndependent Ethics Committee/Research 
Ethics Board ( IRB/ IEC) before study  start. A signed and dated statement that the protocol and 
informed consent have been approved by  [CONTACT_1201]/I ECmust be given to [COMPANY_001] before study 
initiation. Prior to study  start, the investigator is required to sign a protocol signature [CONTACT_144984]/her agreement to conduct the study  in accordance with these documents and all 
of the instructions and procedures found in this protocol and to give access to all relevant data 
and records to [COMPANY_001] monitors, auditors, [COMPANY_001] Clinical Quality  Assurance 
representatives, designated agents of [COMPANY_001], IRBs/IECs/REBs, and regulatory  authorities as 
required. If an inspection of the clinical site is requested by a regulatory  authority , the 
investigator must inform [COMPANY_001] immediately  that this request has been made.
10.4 Publication of study  protocol and results
[COMPANY_001] assures that the key design elements of this protocol will be posted in a publicl y 
accessible database such as clinicaltrials.gov. In addition, upon study  completion and 
finalization of the study  report the results of this trial will be either 
submitted for publication 
and/or posted in a publicly  accessible database of clinical trial results.
[ADDRESS_685088] 
be considered a protocol amendment, and unless such an amendment is agreed upon by 
[CONTACT_6669]/IEC it cannot be implemented. All significant protocol 
deviations will be recorded and reported in the CSR.
11.[ADDRESS_685089] be approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC . Only 
amendments that are required for patient safety  may be implemented prior to IRB/IEC
approval. Notwithstanding the need for approval of formal protocol amendments, the 
investigator is expected to take any immediate action required for the safet y of any patient
included in this study , even if this action represents a deviation from the protocol. In such 
cases, [COMPANY_001] should be notified of this action and the IRB/IEC at the study  site should be 
informed within 10 working day s.

[COMPANY_001] Confidential Page 69
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
12 References (available upon request)
Cohen JA, Barkhof F, Comi G, et al (2010). Oral fingolimod or intramusc ular interferon for 
relapsing multiple sclerosis. The New England Journal of Medicine; 362(5):[ADDRESS_685090] LC, McKenna SP, Meads DM, et al (2005). The s ymptomatic, functional, and quality  
of life impact of multiple sclerosis: Report on a qualitative inv estigation of the 
patients’perspective. Value in Health; 8(6), A135. 
Fischer JS, Jak JS, Kniker JE et al (2001). Multiple Sclerosis Functional Composite (MSFC) 
Administration and scoring manual. Revised, October 2001. National Multiple Sclerosis 
Society .
Kappos L, Radue EW, O’Connor P, et al (2010). A placebo -controlled trial of oral fingolimod 
in relapsing multiple sclerosis. The New England Journal of Medicine; 362(5):387 -401. 
Keegan BM and Noseworthy  JH (2002). Multipl e sclerosis. Annual Review of Medicine; 
53:285 -302.
Panitch, H, Goodin, DS, et al (2002). Randomized, comparative stud y of interferon ß- 1a 
treatment regimens in MS. The EVIDENCE trial. Neurology ; 59:1496 -1506 .
Sospedra M and Martin R (2005). I mmunology  of multiple sclerosis. Annual Review of 
Immunology ; 23:683 -747.
Trapp BD, Peterson J, Ransohoff M, et al (1998). Axonal transection in the lesions of multiple 
sclerosis. The New England Journal of Medicine; 338:278-85.

[COMPANY_001] Confidential Page 70
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
13 Appendices
Appendix 1:  Clinically  notable laboratory  values and vital signs
Only  selected lab parameters identified as notable which have been shown to be sensitive to 
fingolimod exposure are included.
CRITERIA  FOR NOTABLE LA BORA TORY A BNORMA LITIES
Notable Values
Laboratory  Variable Standard Units SI Units
LIVER FUNCTION A ND RELA TED V ARIABLES
SGOT (AST) >82 U/L >82 U/L
SGPT (ALT) >90 U/L >90 U/L
Total bilirubin 2.0 mg/dL 34.2 mol/L
Alkaline Phosphatase >280 U/L >280 U/L
RENA L FUNCTION / META BOLIC AND ELECTROLYTE VA RIABLES
Glucose ` 200 mg/dL 11.11 mmol/L
Creatinine 2.0 mg/dL 176 umol/L
Amylase 300 U/L 300 U/L
Cholesterol 240 mg/dL 6.21 mmol/L
Triglycerides ≥300 mg/dL ≥3.39 mmol/L
BUN ≤ 2 mg/dL
≥ 30 mg/dL≤ 0.7 mmol/L
≥ 10.7 mmol/L
Sodium < 125mEq/L
>154mEq/L< 125mmol/L
>154mmol/L
Chloride ≤85mEq/L
≥119mEq/L≤85mmol/L
≥119mmol/L
Potassium ≤ 3.0 mEq/L
≥ 6.0 mEq/L≤ 3.0 mmol/L
≥ 6.0 mmol/L
Magnesium ≤ 1.0 mg/dL
≥ 3.0 mg/dL≤ 0.40 mmol/L (in all other 
countries)
≤ 0.41 mmol/L (in Canada)
Calcium ≤ 7.5 mg/dL
≥ 11.6 mg/dL≤ 1.87 mmol/L
≥ 2.89 mmol/L
Phosphate ≤ 2.0 mg/dL
≥ 5.3 mg/dL≤ 0.65 mmol/L
≥ 1.71 mmol/L

[COMPANY_001] Confidential Page 71
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Notable Values
HEMA TOLOGY VA RIABLES
Hemoglobin 10.0 g/dL 100 g/L
Platelets (Thrombocy tes) 100 k/mm3
600 k/mm3100 x 109/L
600 x 109/L
Leukocytes (W BCs) 2.0 k/mm3
15 k/mm32.0 x 109/L
15 x 109/L
HEMA TOLOGY VA RIABLES: DIFFERENTIA L
Granuloc ytes (Poly, Neutrophils) 1,000 /mm3
[ZIP_CODE]/mm31 x 109/L
12 x 109/L
Lymphocytes <200/mm3
8000/mm3<0.2 x 109/L
8 x 109/L
Red blood cells <3,300,000 /mm3
>6,800,000 /mm3<3.3 x 1012/L
>6.8 x 1012/L
NOTA BLE VITA L SIGNS
Vital Sign Variable Notable Criteria
Pulse (beats/min) >120bpm or Increase of  15 bpm from baseline
Or
< 50bpm or Decrease of  15 bpm from baseline
Systolic BP (mmHg) 160 mm Hg  or Increase of 20 mm Hg from baseline
Or
90 mm Hg  or Decrease of 20 mm Hg from baseline
Diastolic BP (mmHg) 100 mmHg or Increase of 15 mm Hg from baseline
Or
50 mmHg or Decrease of  15 mm Hg from baseline
Temperature ( °C) >38.3 °C/ 101°F
Body Weight (kg) ±7% from baseline weight

[COMPANY_001] Confidential Page 72
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Appendix 2:  Multiple Sclerosis Functional Composite Measure (MSFC)
MSFC -INSTRUCTIONS
(from the "Administration and Scoring Manual for the Multiple Sclerosis Functional 
Composite Measure (MSFC)" b y Fischer JS et al, 2001)
STAND ARDIZING MSFC A DMINISTRA TION
The MSFC should be administered as close 
to the beginning of a study  visit as possible, but 
definitely  before the patient does a distance walk. MSFC components should be administered 
in the following order:
1.Trial 1, Timed [ADDRESS_685091] 
component of the MSFC administered at each visit. The patient is directed to one end of a 
clearl y marked 25-foot (7.62 m) course and is instructed to walk 25 feet (7.62 meter) as 
quickly  as possible, but safel y. The task is immediately  administered again by [CONTACT_527679]. Patients may use assistive devices when doing this task. 
In clinical trials, it is recommended that the study physician selects the appropri ate assistive 
device for each patient.
MATERI ALS NEEDED
Stopwatch, clipboard, Timed 25-Foot Walk Record Form, marked 25 -foot (7.62 m) distance 
in an unobstructed hallway , assistive device (if needed).
TIME LIMIT PER TRIA L
3 minutes (180 seconds) per trial.

[COMPANY_001] Confidential Page 73
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
INSTRUCTIONS FOR THE [ADDRESS_685092]
DESCRIPTION
The 9-HPT is a quantitative measure of upper extremity  (arm and hand) function. The 9-HPT 
is the second component of the MSFC to be administered. Both the dominant and non-
dominant hands are tested twice (two consecutive 
trials of the dominant hand, followed 
immediately  by [CONTACT_454422]-dominant hand). It is important that the 9-
HPT be administered on a solid table (not a rolling 
hospi[INVESTIGATOR_454326]) and that the small 
rubber feet arefixed under the 9-HPT apparatus (or the apparatus be anchored by [CONTACT_527680]).
MATERI ALS NEEDED
9-HPT apparatus, stopwatch, clipboard, 9- HPT Record Form
TIME LIMIT PER TRIAL
5 minutes (300 seconds)
INSTRUCTIONS FOR THE PA CED AUDITORY SERIA L ADDITION TEST (PASAT)
DESCRIPTI ON
The PASAT is a measure of cognitive function that specifically  assesses auditory  information 
processing speed and flexibility , as well as calculation ability . The PASAT is the last measure 
administered at each visit. It is presented onaudio CD to control the rate of stimulus 
presentation. Single digits are presented every  [ADDRESS_685093] sums given 
(out of 60 possible). To minimize familiarity  with stimulus items in clinical trials and other 
serial studies, two alternate forms have been developed; the order of these should be 
counterbalanced across testing sessions.
MATERIAL S NEEDED
CD play er, audio CD with PASAT stimuli, clipb oard, PASAT Record Forms.

[COMPANY_001] Confidential Page 74
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Appendix 3:  [LOCATION_001] Heart A ssociation Functional Classification
Class I Patients have cardiac disease but without the resulting limitations of physical 
activity . Ordinary  physical activit y does not cause undue fatigue, palpi[INVESTIGATOR_332], 
dyspnea, or anginal pain.
Class II Patients have cardiac disease resulting in slight limitation of physical activity . 
They  are comfortable at rest. Ordinary  physical activity  results in fatigue, 
palpi[INVESTIGATOR_332], dy spnea, or anginal pain.
Class III Patients have cardiac disease resulting in marked limitation of physical 
activity . They  are comfortable at rest. Less than ordinary  physical activity  
causes fatigue, palpi[INVESTIGATOR_332], dy spnea, or anginal pain.
Class I V Patients have cardiac disease resulting in inability to carry on any physical 
activity  without discom fort. Symptoms of cardiac insufficiency  or of the 
anginal syndrome may be present even at rest. If any physical activity  is 
undertaken, discomfort is increased.

[COMPANY_001] Confidential Page 75
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Appendix 4:  Guidance for Monitoring of patients taking their first dose of 
the stud y drug 
Initiation of fingolimod treatment results in a transient decrease in heart rate. After the first 
dose, the heart rate decrease starts within an hour and the Day 1 decline is maximal within 6 
hours. With continued dosing, heart rate returns to baseline within one month of chronic 
treatment .In patients receiving fingolimod 0.5 mg this decrease in heart rate, as measured by 
[CONTACT_117682], averages approximately  8 beats per minute (bpm). Heart rates below [ADDRESS_685094]-degree atrio
-ventricular blocks. Second -degree AV blocks, usually  Mobitz type I 
(Wenckebach) have been observed in less than 0.5% of patients receiving Gileny a 0.5mg in 
clinical trials. The conduction abnormalities typi[INVESTIGATOR_527630], asymptomatic, usuall y 
did not require treatment and resolved within the first 24-hours on treatment. Isolated cases of 
transient, spontaneously resolving complete AV block have 
been reported during post-
marketing use of fingolimod 0.[ADDRESS_685095] -dose administration monitoring is mandatory  for the following patients:
At the Baseline visit, in all patients enrolling into this trial from blinded controlled 
trialsand patients fr om open -label controlled 
trials coming off the comparator arm.
Patients who are off fingolimod treatment for the following durations:
The treatment lasted for 14 day s or less and was interrupted for 1 day  or more, or
The treatment lasted for more than 14 days and less than 29 day s and was interrupted 
for more than 7 consecutive day s, or
The treatment lasted for [ADDRESS_685096]-dose monitoring physician isresponsibl e for monitoring 
following the 1stintake of the study  drug and management of brady cardia symptoms should 
these occur . He/she must review vital signs during 6-hour monitoring, post-dose ECG and 
assess discharge criteria at [ADDRESS_685097] potential risk factors, in particular atrio-ventricular 
(AV) conduction and rhythm 
disorders .The 6-hour ECG will help detect otherwise asymptomatic electrocardiographic 
events (specificall y conduction delay s) prior to discharging the patient from the clinic.
Sitting heart rate and blood pressure should be measured prior to the 1stdose of the study  drug 
and every  hour for at least [ADDRESS_685098] sitting for 5 minutes. Then the sitting 

[COMPANY_001] Confidential Page 76
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
heart rate should be taken. The sitting heart rate and blood pressure measurements should be 
collect edthree times to produce three baseline readings for both heart rate and blood pressure 
(prior to the 1stdose of the study  drug only ). For comparison to the post -dose heart rate values, 
the lowest pre -dose value of heart rate should be used. 
Patients should receive the first dose of the study drug in the outpatient setting and at atime 
which will allow for the required 6-hour post-dose monitoring as well as additional 
monitoring 
beyondthat time point , if ne cessary .
After 6 hours monitoring, patients may be discharge d if all of the following discharge criteria 
are met :
Pulse rate at discharge must be at least 45 bpm
Pulse rate at discharge must not be the lowest hourly  value measured during the 
observation period (suggesting that the maximum pharmacod ynamic effect on the heart is 
not y et manifest)
Patients must have no symptoms associated with decreased pulse rate or rhythm 
abnormalities
ECG at 6 hours should not show any significant abnormalities  (e.g. second -degree or 
third- degree AV block, QTc ≥ 500 ms) 
Should post- dose brady arrhy thmia -related symptoms occur, the patient should be monitored 
until the sy mptoms have resolved. Should a patient require pharmacologic intervention during 
the first dose observation, overnight monitoring with continuous ECG in a medical facility 
should be instituted and the first dose monitoring strategy  should be repeated after the second 
dose of fingolimod. 
Overnight monitoring with continuous ECG is required if the ECG at 6 hours shows a QTc 
interval ≥[ADDRESS_685099] should be sought and overnight monitoring with continuous ECG 
is required under the following circumstances:
The pre -dose ECG shows a QTc interval >470 msec (females) or >450 msec (males) or a 
second degree or higher AV block
The patient has relevant risk factors for QT prolongation, for example, hypokalaemia or 
hypomagnesemia, sick- sinus sy ndrome, or sino -atrial heart block
The patient has known ischemic heart disease, history  of m yocardial infarction, congestive 
heart failure, history  of cardiac arrest, cerebrovascular disease, uncontrolled hypertension 
or severe untreated sleep apnea period
The patient has a history  of recurrent s yncope or symptomatic brad ycardia
For patients concurrently treated with beta-blockers or other heart -rate lowering drugs (such 
as verapamil, diltiazem, digoxin or ivabradine) advice from a cardiologist should be sought 
regarding switch to non heart -rate lowering drugs. If a switch to non -heart rate lowering drugs 
is not possible, overnight continuous ECG monitoring is required.

[COMPANY_001] Confidential Page 77
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
In addition to protocol mandated safet y assessments and monitoring procedures, additional 
procedures and assessments may be required as per local prescribing information and should 
be followed accordingl y.
Patients should have written instruction on when to return to clinic and a 24-hour contact
[CONTACT_527681] (chest pain, dizziness, 
palpi[INVESTIGATOR_814], syncope, nausea and vomiting, etc.).Patients should be instructed not to drive 
themselves after the first dose of study  drug administration.
If a patient requires treatment for bradycardia/b radyarrh ythmia during the first-dose 
observation period, the patient should be hospi[INVESTIGATOR_527631]-
dose monitoring procedures should be repeated for the second dose of study  drug.
Recommendations for management of brady cardia 
Prior to the administration of study  drug, clinicians should be particularl y mindful of patients 
who have a low pulse at baseline or those patients switching to a no n-heart rate lowering drug 
and the advice of a cardiologist should be soug
ht.  
Atropi[INVESTIGATOR_050] (sc or iv) is recommended as the first line treatment of brady cardia, up to a 
maximum daily  dose of 3 mg.
Furthermore, the common guidelines for treatment of bradycardia (e.
g.ACL S guidelines) 
should be followed as appropriate:
In case of clinical s ymptoms or hy potension, administration of atropi[INVESTIGATOR_050] 1 mg, repeated 
administration in 3 -5 minutes .
If heart rate and/or blood pressure remains unresponsive, consider administr ation of 
dopamine drip 5 -20 ug/kg/min or epi[INVESTIGATOR_207368] 2 -10 ug/min.
Performance of transcutaneous pacing may also be considered.
In the setting of decreased blood pressure, isoproterenol should be avoided/used with caution .

[COMPANY_001] Confidential Page 78
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Appendix 5:  Guidance on saf ety monitoring
Guidance on monitoring of patients with elevated blood pressure
Patients who have at least two out of the three sitting readings of blood pressure (systolic BP 
≥140 and/or diastolic BP ≥90 mmHg) should be followed up in one month by  [CONTACT_527682]. Ifsystolic BP ≥140 and/or diastolic BP ≥[ADDRESS_685100] or to the specialt y 
hypertension clinic for evaluation, diagnosis and treatment of hy pertension .
Patients with BP values of >160/[ADDRESS_685101] be 
reported as an AE and discontinuation of the study  drug may be considered by  [CONTACT_093].
Guidance on monitoring of patients with elevated live r function tests
For detailed guidance on handling specific laboratory  or AE pattern, refer to Appendix 6 .
For any unscheduled laboratory  assessments performed locall y, an identical sample should 
also besent to the central laboratory (Study  Part One only)for analysis and capture in the 
central database. 
An interruption or discontinuation of the study drug should be clearly documented and 
reflected on Dosage Administration Record e CRF.  AE/SAEs need to be filed as appropriate.
Guidance on monitoring of patients with notable ly mphopenia 
Fingolimod results in sequestration of a proportion of the circulating lymphocy tes in lymph 
nodes with resultant reduction in circulating lymphocy te counts. Average circu lating 
lymphocy tes counts are expected to be around 0.5 -0.6 x109 /L or 500 -600 cells/mm3.  As such, 
the absolute total WBC, neutrophil and lymphocyte counts will be measured at each visit y. If 
the absolute lymphocy te count drops below 0.2x109/L or 200cells/mm3lymphocy te counts 
should be repeated regularl y, at least monthly , and the patient should be reminded of the risk 
of infections and instruct edto promptly  report any  symptoms of infections to the investigator .
If monthly  site visits create a logistic al burden for the patient, local ly mphocy te testing can be 
performed, with an eCRF comment added that lymphocy te counts were obtained locall y and 
reviewed by [CONTACT_093]. Study  drug should be temporaril y interrupted at the discretion 
of the investiga tor. Recovery  of lymphocy te counts is expected to take approximately  1-2 
months after stoppi[INVESTIGATOR_527632] -life of fingolimod. The patient should be 
evaluated and monitored for infections on a regular basis during this period.
Guidance on monitoring of patients with symptoms of neurological
deterioration, inconsistent with MS course
Should a patient develop any manifestations that, in opi[INVESTIGATOR_871], are atypi[INVESTIGATOR_527633]/signs (e.g. 

[COMPANY_001] Confidential Page 79
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
rapid cognitive decline, behavioral changes, cortical visual disturbances or any other 
neurological cortical symptoms/sign), or any symptom/sign suggestive of an increase of 
intracranial pressure or accelerated neurological deterioration, the investigator should 
schedule a complete physical and neurological examination and an MRI as soon as possible 
and before beginning any steroid treatment. Conventional MRI  as defined in the protocol as 
well as Fluid -attenuated Inversion Reco very (FLAIR) and Diffusion- weighted imaging (DWI) 
sequences are recommended for differential diagnosis of Posterior reversible encephalopath y 
syndrome. The MRI must be evaluated by [CONTACT_527683]. The investigator will 
contact [CONTACT_527684]. AE/SAEs need to be filed as appropriate.
In case of new findings in the MRI  images in comparison with the previous available MRI 
which are not compatible with MS lesions, the study  drug may be discontinued and other 
diagnostic evaluations need to be performed at the discretion of the investigator. In case of 
presence of new hyperintense T2-weighted lesions in the MRI which may be infectious in 
origin it is recommended to collect a cerebrospi[INVESTIGATOR_527634]. Anal ysis of the 
CSF sample including cellular, biochemical and, microbiological analysis (e.g. herpes virus, 
JC virus), to confirm/exclude an infection (e.g. PML ) should be performed . In the event of 
suspected CNS infection, a CSF aliquot should be sent toa central laboratory  (designated by 
[CONTACT_456]) for confirmatory  testing.
Only  when the differential diagnosis evalu ations have excluded other possible diagnosis than 
MS and after discussion with the Medical Advisor at [COMPANY_001], the study  drug may be 
restarted.
Guidance on monitoring of patients with infections
All infections that develop during the study  will be report ed as AEs. Investigators are 
requested to specifically  ask about infections at each visit. Treatment and additional 
evaluations will be performed at discretion of the investigator. 
The investigator should be vigilant for risk of infections including oppor tunistic infections 
(with bacterial (e.g. atypi[INVESTIGATOR_527635]), viral (e.g. HSV, VZV, JCV) , or fungal (e.g. 
cryptococcus agents) , should remind the patient of the risk of infections, and instruct them to 
promptly  report any symptoms of infections to the investigator. The patients must also be 
reminded to alway s carry  their Patient Information Card (with site contact [CONTACT_188667] a clinical study  with an investigational agent with 
potential immunosuppressive effects) and to show this to any local healthcare provider they 
may consult and ask that the investigator be contact[INVESTIGATOR_530]. 
When evaluating a patient with a suspected infection, the most sensitive tests available should 
be used (i.e. that directl y detect the path ogen, as with PCR). 
The investigator should consider early treatment with antimicrobial therapy  on the basis of 
clinical diagnosis or suspi[INVESTIGATOR_123221] (e.g. antiviral treatment for herpes simplex or zoster) in 
consultation with infectious disease experts , as appropriate. 
Investigators should be aware that in the post marketing setting with Gileny a, isolated cases of 
cryptococcal meningitis have been reported. Patients reporting symptoms and signs (such as, 

[COMPANY_001] Confidential Page 80
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
but not limited to, headache accompanied with st uff neck, sensitivity  to light, fever, confusion, 
tiredness, body  aches, chills, vomiting, and/or nausea) consistent with meningitis should 
undergo prompt diagnostic evaluation. If cryptococcal meningitis is diagnosed, appropriate 
treatment should be initiated as soon as possible. The investigator should inform the [COMPANY_001] 
medical expert [INVESTIGATOR_198144] y such cases.
Investigators should consider the added immunosuppressive effects of corticosteroid therap y 
for treatment of MS attack/relapse and increase vigilance regarding infections during such 
therap y and in the weeks following administration.
Profiling of infection risk in study  patients based on anti- viral IgG antibody  test results
As a conservative measure before initiation of any immune -modulating drug, patient swithout 
a history  of chickenpox or without vaccination against varicella zoster virus (VZV) should be 
tested for antibodies to VZV. VZV vaccination of antibody -negative patients should be 
considered prior to commencing treatment with fingolimod, following which initiation of 
study  drug should be postponed for at least [ADDRESS_685102] of vaccination to 
occur.
Serology  testing for antibody  status of varicella zoster virus (VZV) is performed in the study 
to profile infection risk in study  patients. The investigator should inform the patients of their 
immune status based on these serology  results and of the potential risks of primary  infections 
or viral reactivation while taking stud y drug.
A positive IgG antibody  test result does not indica te active infection per se, but only evidence 
of exposure to viral antigens via past infection or vaccination. These patients may,however, 
be at risk for viral reactivation, which may  manifest as VZV virus IgG positive: Shingles.
The investigator should instruct the patient to be alert to and 
report any symptoms orsigns 
suggestive of shingles, so that appropriate antiviral treatment can be initiated in consultation 
with a local infectio us disease expert (if needed). 
It is also important to ask the patient to report if they are exposed to anyone who has recentl y 
received a live or live attenuated vaccine and manifested a skin rash after the vaccination so 
that it can be decided, in consultation with an infectious disease expert, if antiviral therap y is 
warranted. 
It should be noted that live or live attenuated vaccines should be avoided while patients are 
taking study  drug and for [ADDRESS_685103] of vaccination to occur.
Vaccination may be less effective during and for up to two months after treatment with 
fingolimod. 

[COMPANY_001] Confidential Page 81
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Appendix 6:  Liver event and Laboratory  trigger Definitions and Follow -
up Requirements
Liver Event and Laboratory  Trigger Definitions
Definition/ threshold
LIVER LABORATORY TRIGGERS [ADDRESS_685104] < ALT / AST [ADDRESS_685105]
1.[ADDRESS_685106] < TBL [ADDRESS_685107]
LIVER EVENTS ALT or AST > 5 × ULN
ALP > 2 × ULN (in the absence of known bone pathology)
TBL > 2 × ULN (in the absence of known Gilbert syndrome)
ALT or AST > 3 × ULN and INR > 1.5 
Potential Hy’s Law cases (defined as ALT or AST > 3 × ULN and 
TBL > 2 × ULN [mainly conjugated fraction] without notable 
increase in ALP to > 2 × ULN)
Any clinical event of jaundice (or equivalent term)
ALT or AST > 3 × ULN accompanied by (general) malaise, fatigue, 
abdominal pain, nausea, or vomiting, or rash with eo sinophilia
Any adverse event potentially indicative of a liver toxicity*
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -related 
conditions; the non -infectious hepatitis; the benign, malignant and unspecified liver neoplasms
TBL: total bilirubin; ULN: upper limit of normal 
Follo w Up Requirements for Liver Events and Laboratory  Triggers
Criteria Actions required Follow -up monitoring
Potential Hy’s Law 
caseaDiscontinue the study treatment 
immediately
Hospi[INVESTIGATOR_18552], if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP and 
γGT until resolutionc(frequency at 
investigator discretion)
ALT or AST
> 8 × ULN Discontinue the study treatment 
immediately
Hospi[INVESTIGATOR_18553]
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP and 
γGT until resolutionc(frequency at 
investigator discretion)
> 3 × ULN and INR > 
1.5Discontinue the study treatment 
immediately
Hospi[INVESTIGATOR_18552], if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP and 
γGT until resolutionc(frequency at 
investigator discretion)
> 5 to ≤ 8 × ULN Repeat LFT within 48 hours
If elevation persists, continue follow -up 
monitor ing
If elevation persists for more than 2 
weeks, discontinue the study drug
Establish causalityALT, AST, TBL, Alb, PT/INR, ALP and 
γGT until resolutionc(frequency at 
investigator discretion)

[COMPANY_001] Confidential Page 82
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Criteria Actions required Follow -up monitoring
Complete liver CRF
> 3 × ULN 
accompanied by 
[CONTACT_18688]Discontinue the study treatment 
immediately
Hospi[INVESTIGATOR_18553]
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP and 
γGT until resolutionc(frequency at 
investigator discretion)
> 3 to ≤ 5 × ULN 
(patient is 
asymptomatic)Repeat LFT within the next week
If elevation is confirmed, initiate close 
observation of the patientInvestigator discretion
Monitor LFT within 1 to 4 weeks 
ALP (isolated)
> 2 × ULN (in the 
absence of known 
bone pathology)Repeat LFT within 48 hours
If elevation persists, establish causality
Complete liver CRFInvestigator discretion
Monitor LFT within 1 to 4 weeks or at 
next visit
TBL (isolated)
> 2 × ULN (in the 
absence of known 
Gilbert syndrome)Repeat LFT within 48 hours
If elevation persists, discontinue the study 
drug immediately
Hospi[INVESTIGATOR_18553]
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP and 
γGT until resolutionc(frequency at 
investigator discretion)
Test for hemolysis (e.g ., reticulocytes, 
haptoglobin, unconjugated [indirect] 
bilirubin)
> 1.5 to ≤ 2 × ULN
(patient is 
asymptomatic)Repeat LFT within the next week
If elevation is confirmed, initiate close 
observation of the patient Investigator discretion
Monitor LFT within 1 to 4 weeks or at 
next visit
Jaundice Discontinue the study treatment 
immediately
Hospi[INVESTIGATOR_18554]
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP and 
γGT until resolutionc(frequency at 
investigator discretion)
Any AE potentially 
indicative of a liver 
toxicity*Consider study treatment interruption or 
discontinuation 
Hospi[INVESTIGATOR_6549]
Establish causality
Complete liver CRFInvestigator discretion
aElevated ALT/AST > 3 × ULN and TBL > 2 × ULN bu t without notable increase in ALP to > 2 × ULN
b(General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia 
cResolution is defined as an outcome of one of the following: (1) return to baseline values, (2) stable values at 
three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level after a maximum of 6 
months, (4) liver transplantation, and (5) death.

[COMPANY_001] Confidential Page 83
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Appendix 7: Guidance for Ophthalmic Monitoring
Fingolimod has previously  been associated with a two-fold increase in the risk of macular 
edema in renal transplant patients receiving cy closporine. Macular edema occurred in 0.4% of 
patients treated with fingolimod 0.5 mg/day . Approximately  75% of cases occurred within the 
first 3-[ADDRESS_685108] .
2.Optical Coherence Tomography  (OCT) scan should be perform edif considered 
clinically  indicated. OCT is required for patients transferring into this trial from a 
blinded study  with a comparator arm at the Month [ADDRESS_685109]. Patients with history  of uveitis and patients with diabetes mellitus are 
at an increased risk of macular edema and may  require more frequent ophthalmic evaluations, 
per investigator’s discretion.
Based on ophthalmic monitoring during the study , study  drug must be interrupted in any 
patient who meets one of the following criteria:
Patient who is diagnosed to have macular edema.
Patient who has a decrease in visual acuity  ([ADDRESS_685110] chart) and an abnormal OCT (>20% increase in central foveal thickness
compared to baseline OCT or cy stic changes in the fovea).
A fluorescein angiogram is recomm ended to evaluate for the presence of vascular leakage in 
these patients and patients must be encouraged to stay in the study  to track resolution of these 
changes during subsequent visits.  
These patients should be followed- up 1 month and 3 months after d iagnosis of macular edema 
and more frequently ,if needed ,based on the investigator ’s judgment. Further ophthalmologic
evaluations will be conducted until such time as resolution is confirmed or no further 
improvement is expected by  [CONTACT_1964] (ba sed on a follow -up period of not less than 
3 months). These evaluations will include repeat best-corrected visual acuity , fundus 
examination and OCT. Fluorescein angiograph y (FA) is repeated at the discretion of the 

[COMPANY_001] Confidential Page 84
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
ophthalmologist. If the patient does notshow definite signs of improvement on examination 
by [CONTACT_527668] (e.g. OCT, FA) after 6-[ADDRESS_685111] eCRF . AE/SAEs need to be filed as appropriate.  
For patients discontinuing study  drug for any of the above ophthalmic reasons, copi[INVESTIGATOR_527636] y (if performed) as well as source documents of 
ophthalmic examination should be kept at the site as source documents. These documents may 
need to be submitted for review b y an independent panel ,if needed. 
Guidance on monitoring patients with uveitis
Patients with a history  of uveitis or findings compatible with active uveitis at baseline can 
enter the study  given that there is no evidence of macular edema in the baseline ophthalmic 
examination.
In order to specifically  assess the risk of macular edema in the MS population with co-
existing uveitis, each patient with findings in any ophthalmic examination compatible with 
active uveitis (e.g., significant anterior chamber cell or flare, vitreous cell or flare, pars 
planitis, vasculitis, chorioretinitis) under the discretion of the investigator should 
undergo an 
ophthalmic examination. Itis the discretion of the investigator to determine the frequency  of 
these ophthalmic examinations. Adjustments to the schedule can be made to align these 
evaluations with other planned study  visits. 
The diagnosis of macular edema will lead to study  drug interruption (refer to Guidance for 
monitoring of patients with macular edema above).

[COMPANY_001] Confidential Page 85
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
Appendix 8: EDSS A ssessment Criteria
EXPA NDED DISA BILITY STA TUS SCA LE
0 =normal neurological exam (all FS grade 0)
1.0 = no disability , minimal signs in one FS (one FS grade 1)
1.5 = no disability , minimal signs in more than one FS (more than one FS grade 1)
2.0 = minimal disability  in one FS (one FS grade 2, others 0 or 1)
2.5 = minimal disability  in two FS (two FS grade 2, others 0 or 1)
3.0 = moderate disability  in on e FS (one FS grade 3, others 0 or 1) though full y
ambulatory ; or mild disability  in three or four FS (three/four FS grade 2, others 0 or 1)
though full y ambulatory
3.5 = fully  ambulatory  but with moderate disability  in one FS (one FS grade 3) and
mild disa bility  in one or two FS (one/two FS grade 2) and others 0 or 1;
or fully  ambulatory  with two FS grade 3 (others 0 or 1);
or fully  ambulatory  with five FS grade 2 (others 0 or 1)
4.0 = ambulatory  without aid or rest for some 500 meters; up and about some 12 hours a day 
despi[INVESTIGATOR_506292] y severe disability  consisting of one FS grade 4 (others 0 or 1) or 
combinations of lesser grades exceeding limits of previous steps
4.5 = ambulatory  without aid or rest for some 300 meters; up and about much of the day ,
Chara cterized by  [CONTACT_527685] y usually consisting of one FS grade 4
and combination of lesser grades exceeding limits of previous steps
5.0 = ambulatory  without aid or rest for about 200 meters (usual FS equivalents include at
least one FS grade 5, or combinations of lesser grades usually  exceeding
specifications for step 4.5)
5.5 = ambulatory  without aid or rest about 100 meters
6.0 = unilateral assistance (cane or crutch) required to walk about 100 meters with
or without resting
6.5 = constant bilateral assistance (canes or crutches) required to walk at least 20
meters without resting
7.0 = unable to walk 5 meters even with aid, essentiall y restricted to wheelchair;
wheels self and transfers alone; up and about in wheelchair some 12 hours a day
7.5 = unable to take more than a few steps; restricted to wheelchair; may  need some
help in transferring and in wheeling self
8.0 = essentially  restricted to bed or chair or perambulated in wheelchair, but out of
bed most of day ; retains many  self-care fun ctions; generally  has effective use of
arms
8.5 = essentially
 restricted to bed much of the day ; has some effective use of arm(s);
retains some self -care functions
9.0 = helpless bed patient; can communicate and eat

[COMPANY_001] Confidential Page 86
Amended Protocol Version 11 –Clean Protocol No. CFTY720D2399
9.5 = totally  helpless bed patient; unab le to communicate effectivel y or eat/swallow
10.0 = death due to MS
